# Interleukin-22 Polymorphisms inPlasmodium falciparum-Infected Malaria Patients

Authors: Nada H. Aljarba; Mashael R. Al-Anazi; Mohammed I. Shafeai; Fuad H. Rudiny; Saad M. Bin Dajem; Hani Alothaid; Majid Darraj; Saad Alkahtani; Jahad Alghamdi; Mohammed N. Al-Ahdal; Ahmed A. Al-Qahtani
Journal: Mediators of Inflammation
 (2020)

---

## Abstract

Background and Objectives. Malaria infection, caused by Plasmodium falciparum, is the most lethal and frequently culminates in severe clinical complications. Interleukin-22 (IL-22) has been implicated in several diseases including malaria. The objective of this study was to investigate the role of IL-22 gene polymorphisms in P. falciparum infection. Material and Methods. Ten single-nucleotide polymorphisms (SNPs), rs976748, rs1179246, rs2046068, rs1182844, rs2227508, rs2227513, rs2227478, rs2227481, rs2227491, and rs2227483, of IL-22 gene were genotyped through PCR-based assays of 250 P. falciparum-infected patients and 200 healthy controls. In addition, a luciferase reporter assay was done to assess the role of the rs2227513 SNP in IL-22 gene promoter activity. Results. We found that the rs2227481 TT genotype (odds ratio 0.254, confidence interval = 0.097-0.663, P=0.002) and the T allele is associated with protection against P. falciparum malaria as well as the rs2227483 AT genotype (odds ratio 0.375, confidence interval = 0.187-0.754, P=0.004). The haplotype A-T-T of rs1179246, rs1182844, and rs976748 was statistically more frequent in the control group (frequency 41%, P=0.034) as well as the haplotype A-G of rs2046068 and rs2227491 (frequency 49.4%, P=0.041). The variant rs2227513 G allele had a statistically higher activity (P<0.0001) with the luciferase reporter assay. Conclusion. The study suggests that IL-22 polymorphisms in rs2227481 and rs2227483 could contribute to protection against P. falciparum malaria. Also, the G allele of rs2227513, located in the promoter region of IL-22 gene, could be essential for higher expression levels of IL-22 cytokine.


---

## Body

## 1. Introduction

Malaria caused byPlasmodium falciparum is associated with significant morbidity and mortality in humans [1]. It affects 5% of individuals with severe malaria and often culminates in severe clinical complications including severe malarial anemia (SMA), hemoglobinuria, and cerebral malaria (CM) [2]. Malaria is considered a global health threat, with rapidly increasing numbers affecting over 100 nations and more than 219 million people globally. It is estimated that almost 50% of the global population is susceptible to malaria and nearly 1 million individuals die annually from the infection [3].Saudi Arabia is one of the largest countries in the Middle East with a population of over 32 million. The implementation of malaria control measures in Saudi Arabia over the past 50 years, in collaboration with the World Health Organization (WHO), has effectively reduced the magnitude of risk throughout the nation [4–6]. In 2016, Saudi Arabia was included in the “Eliminating Countries for 2020 (E-2020)” initiative of the WHO to achieve the goal of a malaria-free country by 2020 [3]. According to the WHO country profile (2017), there are currently 64 active foci of malaria in Saudi Arabia. The number of individuals living in the active foci is 173,000 (1%) with the majority (32.8 million (99%)), living in malaria-free areas. The predominant Plasmodium species causing the majority of the malaria cases is P. falciparum (97%) followed by P. vivax (2%).It is known that the host genetic polymorphisms play an important role in the variation of malaria severity associated withP. falciparum infection. Also known is the fact that malaria parasites have a robust selective pressure on human genetics, particularly in regions where malaria is endemic [7, 8]. Various disease phenotypes caused by P. falciparumare influenced by host genetic factors and assist in establishing the pathological mechanisms underlying the vulnerability to the infection [9]. For example, single-nucleotide polymorphisms (SNPs) in the tumor necrosis factor-alpha (TNFα) gene are associated with an increase in SMA in P. falciparum-infected patients [10]. SNPs in the TNFα gene have been shown to increase the susceptibility to severe malaria [11].Interleukin-22 (IL-22) has been classified as a cytokine of the IL-20 subfamily. TheIL-22 gene is positioned at chromosome 12q15. Both innate and adaptive arms of the immune system produce IL-22, including αβ T, γδ T, NKT, and innate lymphoid cells (ILCs). Certain nonhematopoietic and myeloid cells can also release IL-22 [12]. IL-22 affects the outcome of several diseases, such as multiple sclerosis [13], psoriasis [14], inflammatory bowel disease (IBD) [14], Guillain-Barré syndrome (GBS) [15], and West Nile encephalitis [16].Polymorphisms in theIL-22 gene are associated with several diseases such as ulcerative colitis (UC) [17], psoriasis vulgaris [18], bladder cancer [19], and systemic lupus erythematosus (SLE) [20]. It has been suggested that the variations contribute to malaria pathogenesis. Koch et al. found an association between a IL-22 polymorphism and vulnerability to CM, with other variations associated with protection [21] and an IL-22 polymorphism, namely rs2227473, was associated with childhood CM pathogenesis [22]. In experimental P. chabaudi malaria infection in mice, a higher production of IL-22 was observed in the liver, which is important as it suggests that this cytokine is an essential factor in the protection against the lethal infection caused by P. chabaudi [23]. Such a finding could suggest an important role for IL-22 in P. falciparum-associated malaria and pathogenesis. Therefore, this report investigates the plausible role of variations at the IL-22 gene in the complications associated with P. falciparum infection in a Saudi Arabian population.


## 2. Materials and Methods

### 2.1. Study Design

Venous blood was collected from 250P. falciparum-infected patients admitted to the Malaria Center in the Jazan region, located in the southwest of Saudi Arabia. The study also included 200 randomly selected uninfected healthy individuals as a control group. A thick blood film from each infected patient was used to determine the parasite density according to the “plus system” scale, described in the WHO manual [24]. Based on the parasite density, patients were categorized in four groups: Group I: 1-10 parasites per 100 thick film fields, Group II: 11-100 parasites per 100 thick film fields, Group III: 1-10 parasites per single thick film field, and Group IV: more than 10 parasites per single thick film field.


### 2.2. Ethics Statement

This study was approved by the Research Ethics Committee at King Fahad Hospital (KFCH), Jazan (Registry number 041) and conducted in accordance with the Helsinki Declaration of 1975. Informed consent were obtained from all participants prior to their participation in the study; consent for children were given by their legal guardians. To ensure confidentiality, patient data and biological samples were anonymized prior to processing by laboratory staff. Basic demographic and clinical data required to accomplish the objectives of this study were collected and securely retained for all study participants.


### 2.3. SNP Selection and Genotyping

A total of ten SNPs within theIL-22 gene region were selected for genotyping. The IL-22 SNPs included were rs976748, rs1179246, rs2046068, rs1182844, rs2227508, rs2227513, rs2227478, rs2227481, rs2227491, and rs2227483. Candidate SNPs were selected based on the following criteria: (i) a minorallelefrequencyMAF≥5%, as reported by the 1000 genome for the combined populations and (ii) a linkage disequilibrium (LD) thresholdr2≤0.8 or (iii) existence of evidence for an association with malaria. Marker information of the SNPs selected is shown in Supplementary Table 1. Genotyping the SNPs was performed using polymerase chain reaction (PCR)-based direct DNA sequencing.DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol and stored at -20°C for further experimentation. The PCR was performed using the GoTaq Green Master Mix PCR (Promega, Madison, WI, USA). Primers flanking SNPs of interest were designed using Primer3 Input (version 0.4.0) (http://bioinfo.ut.ee/primer3-0.4.0/). All primers were tailed with an M13 sequence to facilitate the sequencing of the PCR products. Sequences of the primers and PCR conditions used for each SNP are shown in Supplementary Table 2. The PCR products were detected by 2% gel electrophoresis to ensure the quality of the PCR products. The amplification products were subjected to direct sequencing using a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. Each PCR product was sequenced in the forward and reverse directions. The sequences were analyzed and edited with the SeqMan Pro 15 Lasergene (DNASTAR, Inc., Madison, WI, USA).


### 2.4. Luciferase Reporter Assays to Monitor the Activity of Gene Expression on IL-22 Promotor

Gene fragments of the promoter region containing IL-22 rs2227513 A/G variants were amplified and cloned in the pGL3 Basic Vector (Promega, Madison, WI, USA). Primers were tailed at the 5′ end with specifying endonuclease recognition sites for the restriction enzymes SmaI and BglII (New England Biolabs, Ipswich, MA, USA). In addition, a few overhang sequences (CGCCTA) were added to facilitate restriction enzyme binding. Primers used for the amplification of the promoter region, PCR conditions, and chromosomal locations are shown in Supplementary Table 3. PCR amplification for cloning was conducted using the HotStar DNA Polymerase (Qiagen, Hilden, Germany), following the manufacturer’s protocol. Escherichia coli DH5α competent cells were used for colony selection on ampicillin plates. Clones were selected and DNA was extracted using a QIAamp DNA mini kit (Qiagen, Valencia, CA) following the manufacturer’s instructions. Extracted plasmids with cloned fragments were transfected into HEK293 cells (Human Embryonic Kidney 293 cells), which were harvested and tested for luciferase activity after 48 hours.


### 2.5. Statistical Analysis

The SNPs were analyzed and measures of LD, haplotype frequencies, and MAFs were calculated using the Haploview software (version 4.0) (Broad Institute of MIT and Harvard, Cambridge, MA, USA). The de Finetti program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl) was used to conduct a genotypic association test for all the selected variants as the primary test of association. We also performed the allelic, dominant, and recessive model for each variant to explore the possibility of other models of inheritance. The results were expressed as odds ratios (OR) with 95% confidence intervals (95% CI). Testing of deviation from the Hardy-Weinberg equilibrium (HWE) was performed; rs2227513 was excluded from further analyses due to the significant deviation from HWE (P value < 0.05). The test of association was considered significant if the P value, obtained in a two-tailed test, was <0.05.


## 2.1. Study Design

Venous blood was collected from 250P. falciparum-infected patients admitted to the Malaria Center in the Jazan region, located in the southwest of Saudi Arabia. The study also included 200 randomly selected uninfected healthy individuals as a control group. A thick blood film from each infected patient was used to determine the parasite density according to the “plus system” scale, described in the WHO manual [24]. Based on the parasite density, patients were categorized in four groups: Group I: 1-10 parasites per 100 thick film fields, Group II: 11-100 parasites per 100 thick film fields, Group III: 1-10 parasites per single thick film field, and Group IV: more than 10 parasites per single thick film field.


## 2.2. Ethics Statement

This study was approved by the Research Ethics Committee at King Fahad Hospital (KFCH), Jazan (Registry number 041) and conducted in accordance with the Helsinki Declaration of 1975. Informed consent were obtained from all participants prior to their participation in the study; consent for children were given by their legal guardians. To ensure confidentiality, patient data and biological samples were anonymized prior to processing by laboratory staff. Basic demographic and clinical data required to accomplish the objectives of this study were collected and securely retained for all study participants.


## 2.3. SNP Selection and Genotyping

A total of ten SNPs within theIL-22 gene region were selected for genotyping. The IL-22 SNPs included were rs976748, rs1179246, rs2046068, rs1182844, rs2227508, rs2227513, rs2227478, rs2227481, rs2227491, and rs2227483. Candidate SNPs were selected based on the following criteria: (i) a minorallelefrequencyMAF≥5%, as reported by the 1000 genome for the combined populations and (ii) a linkage disequilibrium (LD) thresholdr2≤0.8 or (iii) existence of evidence for an association with malaria. Marker information of the SNPs selected is shown in Supplementary Table 1. Genotyping the SNPs was performed using polymerase chain reaction (PCR)-based direct DNA sequencing.DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol and stored at -20°C for further experimentation. The PCR was performed using the GoTaq Green Master Mix PCR (Promega, Madison, WI, USA). Primers flanking SNPs of interest were designed using Primer3 Input (version 0.4.0) (http://bioinfo.ut.ee/primer3-0.4.0/). All primers were tailed with an M13 sequence to facilitate the sequencing of the PCR products. Sequences of the primers and PCR conditions used for each SNP are shown in Supplementary Table 2. The PCR products were detected by 2% gel electrophoresis to ensure the quality of the PCR products. The amplification products were subjected to direct sequencing using a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. Each PCR product was sequenced in the forward and reverse directions. The sequences were analyzed and edited with the SeqMan Pro 15 Lasergene (DNASTAR, Inc., Madison, WI, USA).


## 2.4. Luciferase Reporter Assays to Monitor the Activity of Gene Expression on IL-22 Promotor

Gene fragments of the promoter region containing IL-22 rs2227513 A/G variants were amplified and cloned in the pGL3 Basic Vector (Promega, Madison, WI, USA). Primers were tailed at the 5′ end with specifying endonuclease recognition sites for the restriction enzymes SmaI and BglII (New England Biolabs, Ipswich, MA, USA). In addition, a few overhang sequences (CGCCTA) were added to facilitate restriction enzyme binding. Primers used for the amplification of the promoter region, PCR conditions, and chromosomal locations are shown in Supplementary Table 3. PCR amplification for cloning was conducted using the HotStar DNA Polymerase (Qiagen, Hilden, Germany), following the manufacturer’s protocol. Escherichia coli DH5α competent cells were used for colony selection on ampicillin plates. Clones were selected and DNA was extracted using a QIAamp DNA mini kit (Qiagen, Valencia, CA) following the manufacturer’s instructions. Extracted plasmids with cloned fragments were transfected into HEK293 cells (Human Embryonic Kidney 293 cells), which were harvested and tested for luciferase activity after 48 hours.


## 2.5. Statistical Analysis

The SNPs were analyzed and measures of LD, haplotype frequencies, and MAFs were calculated using the Haploview software (version 4.0) (Broad Institute of MIT and Harvard, Cambridge, MA, USA). The de Finetti program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl) was used to conduct a genotypic association test for all the selected variants as the primary test of association. We also performed the allelic, dominant, and recessive model for each variant to explore the possibility of other models of inheritance. The results were expressed as odds ratios (OR) with 95% confidence intervals (95% CI). Testing of deviation from the Hardy-Weinberg equilibrium (HWE) was performed; rs2227513 was excluded from further analyses due to the significant deviation from HWE (P value < 0.05). The test of association was considered significant if the P value, obtained in a two-tailed test, was <0.05.


## 3. Results

### 3.1. The Association of the IL-22 Genotype and Allele Distribution and Risk of P. falciparum Malaria

The genotype distribution of the SNPs in the IL-22 gene between theP. falciparum-infected group and control group was investigated. The frequency of the TT genotype of rs2227481 was significantly higher in the control group compared to the malaria group (8.5% versus 2.4%, OR=0.254; 95% CI 0.097-0.663, χ2=8.9, and P=0.002) (Table 1). In addition, the T allele at variant rs2227481 was statistically higher in the control compared to the malaria group (allele frequency 22.7% versus 16.2%, OR=0.656; 95% CI 0.470-0.916, χ2=6.17, and P=0.013). We also found that the T allele was associated with a lower risk of P. falciparum malaria in a recessive model (OR=0.265; 95% CI 0.102–0.685, χ2=8.52, and P=0.003). For IL-22 variant rs2227483, we identified that the heterozygous AT genotype frequency was significantly higher in the control group in comparison to the patient group (genotype frequency 13% versus 5.2%, OR=0.375; 95% CI 0.187-0.754, χ2=8.05, and P=0.004).Table 1
Genotype distribution and allele frequency of IL-22 SNPs among malaria patients compared to healthy control subjects.
SNPs
Genotype/allele distribution
Control
Patients
OR (95% CI)
χ2
P value
rs976748
TT
193 (96.5%)
236 (94.4%)
Ref
CT
6 (3%)
13 (5.2%)
1.772 (0.661-4.749)
1.33
0.249
CC
1 (0.5%)
1 (0.4%)
0.818 (0.051-13.160)
0.02
0.886
T
392 (98%)
485 (97%)
1.515 (0.636-3.611)
0.89
0.344
C
8 (2%)
15 (3%)
CC+CT vs. TT
1.636 (0.647-4.133)
1.1
0.293
CC vs. CT+TT
1.251 (0.078-20.130)
0.03
0.874
rs1179246
CC
55 (27.5%)
86 (34.4%)
Ref
AC
98 (49%)
112 (44.8%)
0.731 (0.474-1.128)
2.01
0.155
AA
47 (23.5%)
52 (20.8%)
0.708 (0.421-1.190)
1.71
0.191
C
208 (52%)
284 (56.8%)
0.824 (0.633-1.073)
2.07
0.150
A
192 (48%)
216 (43.2%)
AA+AC vs. CC
0.723 (0.482-1.085)
2.46
0.116
AA vs. AC+CC
0.855 (0.547-1.338)
0.47
0.492
rs2046068
AA
104 (52%)
114 (45.6%)
Ref
AC
76 (38%)
111 (44.4%)
1.332 (0.898-1.977)
2.03
0.153
CC
20 (10%)
25 (10%)
1.140 (0.598-2.174)
0.16
0.689
A
284 (71%)
339 (67.8%)
1.163 (0.873-1.548)
1.07
0.301
C
116 (29%)
161 (32.2%)
CC+AC vs. AA
1.292 (0.890-1.876)
1.82
0.177
CC vs. AC+AA
1.000 (0.538-1.859)
0
1
rs1182844
TT
83 (41.5%)
90 (36%)
Ref
AT
95 (47.5%)
120 (48%)
1.165 (0.779-1.741)
0.55
0.456
AA
22 (11%)
40 (16%)
1.677 (0.921-3.054)
2.88
0.089
T
261 (65.3%)
300 (60%)
1.252 (0.953-1.644)
2.61
0.106
A
139 (34.5%)
200 (40%)
AA+AT vs. TT
1.261 (0.861-1.848)
1.42
0.233
AA vs. AT+TT
1.541 (0.883-2.690)
2.34
0.126
rs2227508
AA
140 (70)
166 (66.4%)
Ref
AT
56 (28)
71 (28.4%)
1.069 (0.705-1.621)
0.1
0.752
TT
4 (2)
13 (5.2%)
2.741 (0.874-8.596)
3.22
0.072
A
336 (84)
403 (80.6%)
1.264 (0.893-1.788)
1.75
0.186
T
64 (16)
97 (19.4%)
TT+AT vs. AA
1.181 (0.791-1.762)
0.66
0.415
TT vs. AT+AA
2.333 (0.750-7.264)
3.13
0.076
rs2227478
TT
84 (42%)
100 (40%)
Ref
CT
82 (41%)
115 (46%)
1.178 (0.785-1.767)
0.63
0.428
CC
34 (17%)
35 (14%)
0.865 (0.497-1.505)
0.26
0.606
T
250 (62.5%)
315 (63%)
0.979 (0.746-1.285)
0.02
0.877
C
150 (37.5%)
185 (37%)
CC+CT vs. TT
1.086 (0.744-1.585)
0.18
0.668
CC vs. CT+TT
0.795 (0.476-1.328)
0.77
0.380
rs2227481
CC
126 (63%)
175 (70%)
Ref
CT
57 (28.5%)
69 (27.6%)
0.872 (0.573-1.325)
0.41
0.520
TT
17 (8.5%)
6 (2.4%)
0.254(0.097-0.663)
8.9
0.002
C
309 (77.3%)
419 (83.8%)
0.656 (0.470-0.916)
6.17
0.013
T
91 (22.7%)
81 (16.2%)
TT+CT vs. CC
0.730 (0.492-1.083)
2.46
0.116
TT vs. CT+CC
0.265 (0.102-0.685)
8.52
0.003
rs2227491
AA
60 (30%)
72 (28.8%)
Ref
AG
83 (41.5%)
123 (49.2%)
1.235 (0.794-1.920)
0.88
0.348
GG
57 (28.5%)
55 (22%)
0.804 (0.485-1.332)
0.72
0.396
A
203 (50.8%)
267 (53.4%)
0.899 (0.691-1.170)
0.63
0.429
G
197 (49.2%)
233 (46.6%)
GG+AG vs. AA
1.060 (0.705-1.593)
0.08
0.781
GG vs. AG+AA
0.708 (0.461-1.086)
2.51
0.113
rs2227483
TT
153 (76.5%)
204 (81.6%)
Ref
AT
26 (13%)
13 (5.2%)
0.375 (0.187-0.754)
8.05
0.004
AA
21 (10.5%)
33 (13.2%)
1.179 (0.656-2.117)
0.3
0.582
T
332 (83%)
421 (84.2%)
0.916 (0.643-1.306)
0.23
0.628
A
68 (17%)
79 (15.8%)
AA+AT vs. TT
0.734 (0.465-1.160)
1.76
0.184
AA vs. AT+TT
1.296 (0.724-2.319)
0.77
0.381


### 3.2. The Association of the IL-22 Genotype and Allele Distribution and Risk of Advanced P. falciparum Malaria Based on Parasite Density

The malaria group was classified into four cohorts depicting low to high parasite density: I, II, III, and IV. The rs2227481 CT genotype was significantly higher in cohort IV than in cohorts I+II+III and associated with a higher risk of the more severe form of the disease (genotype frequency 33.1% versus 17.8%,OR=2.208; 95% CI 1.170-4.170, χ2=6.13, and P=0.013) (Table 2). In addition, the T allele was associated with a higher vulnerability to develop advanced P. falciparum malaria infection in a dominant model (OR=1.833; 95% CI 1.012-3.322, χ2=4.05, and P=0.044). The IL-22 SNPs were examined in cohort I compared to cohort II+III+IV and cohort I+II compared to cohorts III+IV; however, none of the SNPs showed any statistically significant distribution between the groups (Supplementary Tables 4 and 5).Table 2
Genotype distribution and allele frequency of IL-22 SNPs in group I+II+III of parasite density compared to group IV.
SNPs
Genotype/allele distribution
Group I+II+III
Group IV
OR (95% CI)
χ2
P value
rs976748
TT
86 (95.6%)
150 (93.8%)
Ref
CT
4 (4.4%)
9 (5.6%)
1.290 (0.386-4.314)
0.17
0.678
CC
0 (0%)
1 (0.6%)
1.724 (0.069-42.790)
0.57
0.449
T
176 (97.8%)
309 (96.6%)
1.566 (0.491-4.993)
0.58
0.444
C
4 (2.2%)
11 (3.4%)
CC+CT vs. TT
1.433 (0.436-4.709)
0.36
0.551
CC vs. CT+TT
0.587 (0.024-14.571)
0.56
0.452
rs1179246
CC
28 (31.1%)
57 (35.6%)
Ref
AC
43 (47.8%)
69 (43.1%)
0.788 (0.436-1.424)
0.62
0.429
AA
19 (21.1%)
34 (21.3%)
0.879 (0.427-1.808)
0.12
0.725
C
99 (55%)
183 (57.2%)
0.915 (0.633-1.322)
0.22
0.635
A
81 (45%)
137 (42.8%)
AA+AC vs. CC
0.816 (0.470-1.416)
0.52
0.469
AA vs. AC+CC
1.008 (0.536-1.898)
0
0.979
rs2046068
AA
39 (43.3%)
75 (46.9%)
Ref
AC
44 (48.9%)
67 (41.9%)
0.792 (0.460-1.362)
0.71
0.398
CC
7 (7.8%)
18 (11.2%)
1.337 (0.515-3.475)
0.36
0.550
A
122 (67.8%)
217 (67.8%)
0.998 (0.675-1.476)
0
0.993
C
58 (32.2%)
103 (32.2%)
CC+AC vs. AA
0.867 (0.515-1.458)
0.29
0.589
CC vs. AC+AA
1.503 (0.603-3.749)
0.77
0.379
rs1182844
TT
27 (30%)
63 (39.4%)
Ref
AT
46 (51.1%)
74 (46.2%)
0.689(0.385-1.234)
1.57
0.209
AA
17 (18.9%)
23 (14.4%)
0.580 (0.268-1.255)
1.93
0.164
T
100 (55.6%)
200 (62.5%)
0.750 (0.518-1.087)
2.31
0.128
A
80 (44.4%)
120 (37.5%)
AA+AT vs. TT
0.660 (0.380-1.145)
2.2
0.138
AA vs. AT+TT
0.721 (0.362-1.435)
0.87
0.350
rs2227508
AA
57 (63.3%)
109 (68.1%)
Ref
AT
26 (28.9%)
45 (28.1%)
0.905 (0.507-1.616)
0.11
0.735
TT
7 (7.8%)
6 (3.8%)
0.448 (0.144-1.397)
2
0.157
A
140 (77.8%)
263 (82.2%)
0.759 (0.482-1.194)
1.43
0.231
T
40 (22.2%)
57 (17.8%)
TT+AT vs. AA
0.808 (0.470-1.390)
0.59
0.441
TT vs. AT+AA
0.462 (0.150-1.420)
1.9
0.168
rs2227478
TT
35 (38.9%)
65 (40.6%)
Ref
CT
38 (42.2%)
77 (48.1%)
1.091 (0.620-1.921)
0.09
0.762
CC
17 (18.9%)
18 (11.3%)
0.570(0.261-1.244)
2.02
0.155
T
108 (60%)
207 (64.7%)
0.819 (0.562-1.193)
1.09
0.297
C
72 (40%)
113 (35.3%)
CC+CT vs. TT
0.930 (0.548-1.577)
0.07
0.787
CC vs. CT+TT
0.544 (0.265-1.119)
2.79
0.094
rs2227481
CC
70 (77.8%)
105 (65.6%)
Ref
CT
16 (17.8%)
53 (33.1%)
2.208 (1.170-4.170)
6.13
0.013
TT
4 (4.4%)
2 (1.3%)
0.333 (0.059-1.869)
1.71
0.191
C
156 (86.7%)
263 (82.2%)
1.409 (0.841-2.361)
1.7
0.191
T
24 (13.3%)
57 (17.8%)
TT+CT vs. CC
1.833 (1.012-3.322)
4.05
0.044
TT vs. CT+CC
0.272 (0.0488-1.516)
2.51
0.113
rs2227491
AA
24 (26.7%)
48 (30%)
Ref
AG
49 (54.4%)
74 (46.2%)
0.755 (0.411-1.388)
0.82
0.365
GG
17 (18.9%)
38 (23.8%)
1.118 (0526-2.373)
0.08
0.772
A
97 (53.9%)
170 (53.1%)
1.031 (0.715-1.487)
0.03
0.869
G
83 (46.1%)
150 (46.9%)
GG+AG vs. AA
0.848 (0.477-1.510)
0.31
0.576
GG vs. AG+AA
1.338 (0.704-2.540)
0.79
0.373
rs2227483
TT
73 (81.1%)
131 (81.9%)
Ref
AT
4 (4.4%)
9 (5.6%)
1.254 (0.373-4.213)
0.13
0.714
AA
13 (14.5%)
20 (12.5%)
0.857 (0.403-1.823)
0.16
0.689
T
150 (83.3%)
271 (84.7%)
0.904 (0.550-1.485)
0.16
0.690
A
30 (16.7%)
49 (15.3%)
AA+AT vs. TT
0.951 (0.490-1.846)
0.02
0.881
AA vs. AT+TT
0.846 (0.399-1.794)
0.19
0.662


### 3.3. The Association of the IL-22 Genotype and Allele Distribution Based on the Age of Infected Patients

A comparison of the malaria group in the 1-5 year age group with the 6 years and older age group indicated that the frequency of the rs2046068 A allele was statistically lower in the 6 years and older group (67% versus 92.9%,OR=6.380; 95% CI 0.827-49.203, χ2=4.14, and P=0.044). Also, the rs2046068 A allele was significant in a dominant model (OR=7.5; 95% CI 0.889-63.242, χ2=4.67, and P=0.030) (Table 3).Table 3
Genotype distribution and allele frequency of IL-22 SNPs in group 1-5 years of age compared to 6 years and above age group.
SNPs
Genotype/allele distribution
1-5 years
6 years and above
OR (95% CI)
χ2
P value
rs976748
TT
7 (100%)
229 (94.3%)
Ref
CT
0 (0%)
13 (5.3%)
0.882 (0.048-16.276)
0.4
0.528
CC
0 (0%)
1 (0.4%)
0.098 (0.004-2.611)
0.03
0.861
T
14 (100%)
471 (97%)
0.953 (0.054-16.717)
0.45
1
C
0 (0%)
15 (3%)
CC+CT vs. TT
0.948 (0.052-17.423)
0.43
0.513
CC vs. CT+TT
0.093 (0.004-2.471)
0.03
0.864
rs1179246
CC
2 (28.6%)
85 (35%)
Ref
AC
5 (71.4%)
107 (44%)
0.504 (0.095-2.660)
0.68
0.410
AA
0 (0%)
51 (21%)
3.012 (0.142-63.975)
1.19
0.275
C
9 (64.3%)
277 (57%)
1.358 (0.449-4.112)
0.3
0.586
A
5 (35.7%)
209 (43%)
AA+AC vs. CC
0.744 (0.141-3.914)
0.12
0.725
AA vs. AC+CC
4.013 (0.225-71.433)
1.85
0.174
rs2046068
AA
6 (85.7%)
108 (44.4%)
Ref
AC
1 (14.3%)
110 (45.3%)
6.111 (0.724-51.609)
3.55
0.059
CC
0 (0%)
25 (10.3%)
3.055 (0.167-56.007)
1.38
0.240
A
13 (92.9%)
326 (67%)
6.380 (0.827-49.203)
4.14
0.044
C
1 (7.1%)
160 (33%)
CC+AC vs. AA
7.500(0.889-63.242)
4.67
0.030
CC vs. AC+AA
1.751 (0.097-31.562)
0.8
0.371
rs1182844
TT
3 (42.9%)
87 (35.8%)
Ref
AT
4 (57.1%)
116 (47.7%)
1.00 (0.218-4.584)
0
1
AA
0 (0%)
40 (16.5%)
3.240 (0.164-64.205)
1.36
0.242
T
10 (71.4%)
290 (59.7%)
1.690 (0.523-5.464)
0.78
0.375
A
4 (28.6%)
196 (40.3%)
AA+AT vs. TT
1.345 (0.294-6.147)
0.15
0.701
AA vs. AT+TT
2.985 (0.167-53.317)
1.37
0.241
rs2227508
AA
6 (85.7%)
160 (65.8%)
Ref
AT
1 (14.3%)
70 (28.8%)
2.625 (0.310-22.212)
0.84
0.358
TT
0 (0%)
13 (5.4%)
1.093 (0.058-20.469)
0.49
0.485
A
13 (92.9%)
390 (80.2%)
3.200 (0.414-24.762)
1.38
0.323
T
1 (7.1%)
96 (19.8%)
TT+AT vs. AA
3.112 (0.369-26.284)
1.2
0.272
TT vs. AT+AA
0.879 (0.047-16.206)
0.4
0.529
rs2227478
TT
5 (71.4%)
95 (39.1%)
Ref
CT
2 (28.6%)
113 (46.5%)
2.974 (0.564-15.677)
1.81
0.179
CC
0 (0%)
35 (14.4%)
4.089 (0.220-75.860)
1.82
0.177
T
12 (85.7%)
303 (62.3%)
3.624 (0.802-16.374)
3.19
0.074
C
2 (14.3%)
183 (37.7%)
CC+CT vs. TT
3.895 (0.741-20.482)
2.96
0.085
CC vs. CT+TT
2.554 (0.143-45.516)
1.17
0.278
rs2227481
CC
6 (85.7%)
169 (69.5%)
Ref
CT
1 (14.3%)
68 (28%)
2.414 (0.285-20.430)
0.7
0.404
TT
0 (0%)
6 (2.5%)
0.499 (0.025-9.827)
0.21
0.644
C
13 (92.9%)
406 (83.5%)
2.562 (0.330-19.859)
0.87
0.710
T
1 (7.1%)
80 (16.5%)
TT+CT vs. CC
2.627 (0.311-22.209)
0.85
0.357
TT vs. CT+CC
0.411 (0.0211-7.977)
0.18
0.673
rs2227491
AA
3 (42.9%)
72 (29.6%)
Ref
AG
4 (57.1%)
119 (49%)
1.240 (0.270-5.698)
0.08
0.782
GG
0 (0%)
52 (21.4%)
5.069 (0.256-100.237)
2.13
0.144
A
10 (71.4%)
263 (54.1%)
2.120 (0.656-6.852)
1.65
0.199
G
4 (28.6%)
223 (45.9%)
GG+AG vs. AA
1.781 (0.389-8.161)
0.57
0.451
GG vs. AG+AA
4.112 (0.231-73.184)
1.89
0.169
rs2227483
TT
5 (71.4%)
199 (81.9%)
Ref
AT
0 (0%)
13 (5.3%)
0.744 (0.039-14.180)
0.33
0.567
AA
2 (28.6%)
31 (12.8%)
0.389 (0.072-2.096)
1.29
0.255
T
10 (71.4%)
411 (84.6%)
0.456 (0.139-1.493)
1.77
0.252
A
4 (28.6%)
75 (15.4%)
AA+AT vs. TT
0.553 (0.104-2.942)
0.5
0.481
AA vs. AT+TT
0.365 (0.068-1.966)
1.49
0.222Comparing the malaria group in a 1-9 years age group with a 10 years and older age group, the frequency of the rs976748 CT genotype was significantly higher in the 1-9 years age group compared to the other group (genotype frequency 16.7% versus 4.3%,OR=0.226; 95% CI 0.056-0.910, χ2=5.14, and P=0.023) (Table 4). Under a dominant mode of inheritance, rs976748 was associated with a higher risk of P. falciparum malaria infection in the 10 years and older age group (OR=0.249; 95% CI 0.063-0.989, χ2=4.49, and P=0.034). The rs2227478 CT genotype was substantially elevated in the 10 years and older age group malaria compared to the younger age group (genotype frequency 47.8% versus 22.2%, OR=3.430; 95% CI 1.056-11.138, χ2=4.66, and P=0.030) (Table 4). Similarly, the A allele of SNP rs2046068 was more frequent in the 1-9 years age group (83.3% versus 66.6%, OR=2.508; 95% CI 1.022-6.154, χ2=4.29, and P=0.038), with the T allele of rs2227483 associated with the 10 years and older age group (85.3% versus 69.4%, OR=0.390; 95% CI 0.184-0.830, χ2=6.35, and P=0.011).Table 4
Genotype distribution and allele frequency of IL-22 SNPs in group 1-9 years of age compared to 10 years and above age group.
SNPs
Genotype/allele distribution
1-9 years
10 years and above
OR (95% CI)
χ2
P value
rs976748
TT
15 (83.3%)
221 (95.3%)
Ref
CT
3 (16.7%)
10 (4.3%)
0.226 (0.056-0.910)
5.14
0.023
CC
0 (0%)
1 (0.4%)
0.210 (0.008-5.370)
0.07
0.794
T
33 (91.7%)
452 (97.4%)
0.292 (0.079-1.086)
3.79
0.085
C
3 (8.3%)
12 (2.6%)
CC+CT vs. TT
0.249 (0.063-0.989)
4.49
0.034
CC vs. CT+TT
0.240 (0.009-6.094)
0.08
0.780
rs1179246
CC
5 (27.8%)
80 (34.5%)
Ref
AC
8 (44.4%)
104 (44.8%)
0.812 (0.256-2.578)
0.12
0.724
AA
5 (27.8%)
48 (20.7%)
0.600 (0.165-2.180)
0.61
0.433
C
18 (50%)
264 (56.9%)
0.758 (0.384-1.493)
0.65
0.421
A
18 (50%)
200 (43.1%)
AA+AC vs. CC
0.731 (0.252-2.123)
0.33
0.562
AA vs. AC+CC
10.678 (0.231-1.996)
0.5
0.478
rs2046068
AA
12 (66.7%)
102 (44%)
Ref
AC
6 (33.3%)
105 (45.3%)
2.059 (0.745-5.693)
2
0.156
CC
0 (0%)
25 (10.7%)
6.220 (0.356-108.579)
2.88
0.089
A
30 (83.3%)
309 (66.6%)
2.508 (1.022-6.154)
4.29
0.038
C
6 (16.7%)
155 (33.4%)
CC+AC vs. AA
2.549(0.925-7.024)
3.47
0.062
CC vs. AC+AA
4.547 (0.266-77.748)
2.16
0.142
rs1182844
TT
7 (38.9%)
83 (35.8%)
Ref
AT
11 (61.1%)
109 (41%)
0.836 (0.311-2.248)
0.13
0.721
AA
0 (0%)
40 (17.2%)
7.275 (0.405-130.544)
3.29
0.069
T
25 (69.4%)
275 (59.3%)
1.562 (0.751-3.251)
1.44
0.229
A
11 (30.6%)
189 (40.7%)
AA+AT vs. TT
1.142 (0.427-3.059)
0.07
0.790
AA vs. AT+TT
7.784 (0.459-131.835)
3.69
0.054
rs2227508
AA
14 (77.8%)
152 (65.5%)
Ref
AT
4 (22.2%)
67 (28.9%)
1.543 (0.490-4.861)
0.56
0.456
TT
0 (0%)
13 (5.6%)
2.567 (0.145-45.441)
1.19
0.275
A
32 (88.9%)
371 (80%)
2.005 (0.692-5.811)
1.7
0.191
T
4 (11.1%)
93 (20%)
TT+AT vs. AA
1.842 (0.587-5.781)
1.13
0.288
TT vs. AT+AA
2.276 (0.130-39.829)
1.06
0.302
rs2227478
TT
11 (61.1%)
89 (38.4%)
Ref
CT
4 (22.2%)
111 (47.8%)
3.430 (1.056-11.138)
4.66
0.030
CC
3 (16.7%)
32 (13.8%)
1.318 (0.346-5.030)
0.16
0.685
T
26 (72.2%)
289 (62.3%)
1.574 (0.741-3.343)
1.42
0.234
C
10 (27.8%)
175 (37.7%)
CC+CT vs. TT
2.525 (0.944-6.754)
3.6
0.057
CC vs. CT+TT
0.800 (0.219-2.919)
0.11
0.735
rs2227481
CC
13 (72.2%)
162 (69.8%)
Ref
CT
4 (22.2%)
65 (28%)
1.304 (0.410-4.147)
0.2
0.652
TT
1 (5.6%)
5 (2.2%)
0.401 (0.044-3.695)
0.69
0.404
C
30 (83.3%)
389 (83.8%)
0.964(0.388-2.397)
0.01
0.937
T
6 (16.7%)
75 (16.2%)
TT+CT vs. CC
1.123 (0.386-3.271)
0.05
0.830
TT vs. CT+CC
0.374 (0.041-3.389)
0.82
0.363
rs2227491
AA
5 (27.7%)
71 (30.6%)
Ref
AG
12 (66.7%)
111 (47.8%)
0.651 (0.220-1.928)
0.61
0.435
GG
1 (5.6%)
50 (21.6%)
3.52 (0.399-31.065)
1.45
0.229
A
22 (61.1%)
253 (54.5%)
1.311 (0.654-2.625)
0.59
0.444
G
14 (38.9%)
211 (45.5%)
GG+AG vs. AA
0.872(0.300-2.539)
0.06
0.801
GG vs. AG+AA
4.670 (0.607-35.952)
2.63
0.104
rs2227483
TT
12 (66.7%)
192 (82.8%)
Ref
AT
1 (5.6%)
12 (5.2%)
0.750 (0.090-6.259)
0.07
0.789
AA
5 (27.7%)
28 (12%)
0.350 (0.115-1.068)
3.67
0.055
T
25 (69.4%)
396 (85.3%)
0.390 (0.184-0.830)
6.35
0.011
A
11 (30.6%)
68 (14.7%)
AA+AT vs. TT
0.417 (0.148-1.176)
2.88
0.089
AA vs. AT+TT
0.357 (0.118-1.077)
3.6
0.057No relationship was observed between the IL-22 SNPs and the risk ofP. falciparum malaria comparing the malaria group in the 10-20 years age group with the 21 years and older group (Supplementary Table 6). Finally, we investigated whether the IL-22 gene SNPs significantly differed in frequency between the P. falciparum malaria group, 1-9 years age group, and 41 years and older age group (Table 5). We found that the IL-22 rs2046068 A allele was significantly associated with a higher risk of P. falciparum malaria in the 1-9 years age group. In addition, the A allele of rs2046068 was statistically higher in the 1-9 years age group compared to the 41 years and older age group (allele frequency 83.3% versus 65.7%, OR=2.606; 95% CI 0.995-6.821, χ2=3.99, and P=0.045). No dominant or recessive statistically significant relationship was observed between the two groups. In contrast, the IL-22 rs2227483 T allele was associated with a high susceptibility to develop P. falciparum malaria in the 41 years and older age group with a higher frequency of the rs2227483 T allele (allele frequency 86.1% versus 69.4%, OR=0.367; 95% CI 0.150-0.897, χ2=5.07, and P=0.024). For both SNPs, no dominant or recessive relationship was detected.Table 5
Genotype distribution and allele frequency of IL-22 SNPs in group 1-9 years of age compared to 41 years and above age group.
SNPs
Genotype/allele distribution
1-9 years
41 years and above
OR (95% CI)
χ2
P value
rs976748
TT
15 (83.3%)
49 (90.7%)
Ref
CT
3 (16.7%)
5 (9.3%)
0.510 (0.109-2.389)
0.75
0.386
CC
0 (0%)
0 (0%)
0.313 (0.006-16.446)
Nan
1
T
33 (91.7%)
103 (95.4%)
0.534 (0.121-2.355)
0.71
0.412
C
3 (8.3%)
5 (4.6%)
CC+CT vs. TT
0.510 (0.109-2.389)
0.75
0.386
CC vs. CT+TT
0.339 (0.007-17.723)
Nan
1
rs1179246
CC
5 (27.8%)
25 (46.3%)
Ref
AC
8 (44.4%)
16 (29.6%)
0.400 (0.111-1.441)
2.03
0.154
AA
5 (27.8%)
13 (24.1%)
0.520 (0.127-2.128)
0.84
0.358
C
18 (50%)
66 (61.1%)
0.636 (0.298-1.360)
1.37
0.241
A
18 (50%)
42 (38.9%)
AA+AC vs. CC
0.446 (0.140-1.426)
1.9
0.167
AA vs. AC+CC
0.824 (0.247-2.752)
0.1
0.753
rs2046068
AA
12 (66.7%)
25 (46.3%)
Ref
AC
6 (33.3%)
21 (38.9%)
1.680 (0.538-5.247)
0.8
0.369
CC
0 (0%)
8 (14.8%)
8.333 (0.444-156.275)
3.54
0.059
A
30 (83.3%)
71 (65.7%)
2.606 (0.995-6.821)
3.99
0.045
C
6 (16.7%)
37 (34.3%)
CC+AC vs. AA
2.320(0.760-7.085)
2.24
0.134
CC vs. AC+AA
6.763 (0.371-123.24)
3
0.083
rs1182844
TT
7 (38.9%)
20 (37%)
Ref
AT
11 (61.1%)
22 (40.7%)
0.700 (0.227-2.155)
0.39
0.533
AA
0 (0%)
12 (22.2%)
9.146 (0.480-174.374)
3.79
0.051
T
25 (69.4%)
62 (57.4%)
1.686 (0.754-3.772)
1.64
0.200
A
11 (30.6%)
46 (42.6%)
AA+AT vs. TT
1.082 (0.361-3.240)
0.02
0.888
AA vs. AT+TT
10.882 (0.612-193.665)
4.8
0.028
rs2227508
AA
14 (77.8%)
36 (66.7%)
Ref
AT
4 (22.2%)
14 (25.9%)
1.361 (0.382-4.852)
0.23
0.633
TT
0 (0%)
4 (7.4%)
3.757 (0.181-70.702)
1.51
0.218
A
32 (88.9%)
86 (79.6%)
2.047 (0.654-6.399)
1.56
0.211
T
4 (11.1%)
22 (20.4%)
TT+AT vs. AA
1.750 (0.503-6.089)
0.79
0.375
TT vs. AT+AA
3.297 (0.169-64.262)
1.41
0.234
rs2227478
TT
11 (61.1%)
24 (44.4%)
Ref
CT
4 (22.2%)
20 (37%)
2.292 (0.631-8.317)
1.64
0.200
CC
3 (16.7%)
10 (18.5%)
1.528 (0.350-6.674)
0.32
0.571
T
26 (72.2%)
68 (63%)
1.529(0.669-3.498)
1.02
0.312
C
10 (27.8%)
40 (37%)
CC+CT vs. TT
1.964 (0.661-5.837)
1.5
0.220
CC vs. CT+TT
1.136 (0.276-4.688)
0.03
0.859
rs2227481
CC
13 (72.2%)
38 (70.4%)
Ref
CT
4 (22.2%)
13 (24.1%)
1.112 (0.307-4.021)
0.03
0.871
TT
1 (5.6%)
3 (5.5%)
1.026 (0.098-10.752)
0
0.982
C
30 (83.3%)
89 (82.4%)
1.067 (0.390-2.921)
0.02
0.898
T
6 (16.7%)
19 (17.6%)
TT+CT vs. CC
1.095 (0.335-3.582)
0.02
0.881
TT vs. CT+CC
1.00 (0.097-10.265)
0
1
rs2227491
AA
5 (27.7%)
20 (37%)
Ref
AG
12 (66.7%)
22 (40.7%)
0.458 (0.137-1.531)
1.64
0.199
GG
1 (5.6%)
12 (22.2%)
3 (0.312-28.841)
0.97
0.336
A
22 (61.1%)
62 (57.4%)
1.166 (0.539-2.521)
0.15
0.696
G
14 (38.9%)
46 (42.6%)
GG+AG vs. AA
0.6654 (0.203-2.107)
0.51
0.474
GG vs. AG+AA
4.857 (0.585-40.32)
2.53
0.111
rs2227483
TT
12 (66.7%)
46 (85.2%)
Ref
AT
1 (5.6%)
1 (1.9%)
0.261 (0.015-4.481)
0.98
0.322
AA
5 (27.7%)
7 (12.9%)
0.365(0.098-1.356)
2.38
0.122
T
25 (69.4%)
93 (86.1%)
0.367 (0.150-0.897)
5.07
0.024
A
11 (30.6%)
15 (13.9%)
AA+AT vs. TT
0.348 (0.101-1.195)
2.96
0.085
AA vs. AT+TT
0.387 (0.105-1.423)
2.13
0.144


### 3.4. The Association of the IL-22 Haplotype and Risk of P. falciparum-Associated Malaria

A haplotype analysis was done between theP. falciparum-infected group and the control group and two blocks were generated. Block 1 comprised the IL-22 polymorphisms rs1179246, rs1182844, and rs976748, with block 2 consisting of IL-22 polymorphisms rs2046068 and rs2227491 (Table 6). One haplotype in block 1 was statistically significant. The haplotype A-T-T involving the alleles of rs1179246, rs1182844, and rs976748 was statistically more frequent in the control group than the malaria group (frequency 41%, P=0.034). In block 2, one haplotype A-G of rs2046068 and rs2227491 was statistically significant and prevalent in the control group but not in the malaria group (Frequency 49.4%, P=0.041).Table 6
Haplotypes of IL-22 gene when control group was compared to patients’ group.
Haplotype (block 1)
Freq.
Case, control ratio counts
Case, control frequencies
Chi square
P value
rs1179246
rs1182844
rs976748
A
T
T
0.41
189.3 : 310.7, 179.3 : 220.7
0.379, 0.448
4.465
0.034
C
A
T
0.356
186.3 : 313.7, 134.3 : 265.7
0.373, 0.336
1.312
0.252
C
T
T
0.188
95.7 : 404.3, 73.7 : 326.3
0.191, 0.184
0.075
0.783
A
T
C
0.026
15.0 : 485.0, 8.0 : 392.0
0.030, 0.020
0.892
0.344
A
A
T
0.02
13.7 : 486.3, 4.7 : 395.3
0.027, 0.012
2.733
0.098
Haplotype (block 2)
rs2046068
rs2227491
A
G
0.494
231.9 : 268.1, 212.9 : 187.1
0.464, 0.532
4.174
0.041
C
A
0.306
159.9 : 340.1, 115.9 : 284.1
0.320, 0.290
0.94
0.332
A
A
0.198
107.1 : 392.9, 71.1 : 328.9
0.214, 0.178
1.866
0.171


### 3.5. The Association of the IL-22 Haplotype and Risk of Advanced P. falciparum Malaria Based on Parasite Density

A haplotype analysis was performed between cohort I+II and cohort III+IV of varied parasite density (Table7). The distribution of only one haplotype was found to be significantly different in the groups. The haplotype C-A-C-A-C-C including alleles of rs1179246, rs1182844, rs2046068, rs2227491, rs2227481, and rs2227478 occurred more frequently in cohort I+II (frequency 13.7%, P=0.036).Table 7
Haplotypes of IL-22 gene when group I+II of parasite density was compared to group III+IV.
Haplotypes
Freq.
Case, control ratio counts
Case, control frequencies
Chi square
P value
rs1179246
rs1182844
rs2046068
rs2227491
rs2227481
rs2227478
A
T
A
G
C
T
0.374
158.1 : 265.9, 28.7 : 47.3
0.373, 0.378
0.007
0.933
C
A
A
A
C
T
0.145
63.9 : 360.1, 8.6 : 67.4
0.151, 0.113
0.732
0.392
C
A
C
A
C
C
0.137
52.3 : 371.7, 16.2 : 59.8
0.123, 0.213
4.386
0.036
C
T
C
A
T
C
0.1
44.8 : 379.2, 5.2 : 70.8
0.106, 0.069
0.959
0.327
C
A
A
A
C
C
0.038
16.9 : 407.1, 2.3 : 73.7
0.040, 0.030
0.178
0.672
C
A
C
A
C
T
0.032
15.9 : 408.1, 0.2 : 75.8
0.037, 0.003
2.457
0.117
C
T
C
A
C
C
0.017
6.6 : 417.4, 1.9 : 74.1
0.016, 0.025
0.323
0.569
C
T
A
G
C
T
0.017
6.8 : 417.2, 1.4 : 74.6
0.016, 0.019
0.024
0.877
A
T
A
G
C
C
0.016
6.9 : 417.1, 1.3 : 74.7
0.016, 0.017
0.003
0.955
C
T
A
G
C
C
0.015
7.4 : 416.6, 0.0 : 76.0
0.018, 0.000
1.312
0.252
C
T
A
G
T
C
0.014
7.1 : 416.9, 0.0 : 76.0
0.017, 0.000
1.292
0.255
C
T
A
G
C
C
0.013
4.5 : 419.5, 1.7 : 74.3
0.011, 0.023
0.778
0.377
A
A
C
A
C
C
0.012
5.8 : 418.2, 0.1 : 75.9
0.014, 0.001
0.869
0.351


### 3.6. The Association of the IL-22 Haplotype and Risk of Malaria Based on Age Groups

A haplotype distribution analysis was done in the malaria group for two age groups, 1-5 years and 6 years and older. The frequency of two haplotypes was found to be either statistically significant or close to significance (Table8). The haplotype A-G of rs2046068 and rs2227491 was more frequent in the 1-5 years age group (frequency 46.3%, P=0.056). However, the haplotype C-A of rs2046068 and rs2227491 was significantly high in the 6 years and older age group (frequency 31.9%, P=0.043).Table 8
Haplotypes of IL-22 gene when group 1-5 years of age was compared to 6 years and above.
Haplotypes
Freq.
Case, control ratio counts
Case, control frequencies
Chi square
P value
rs2046068
rs2227491
A
G
0.463
221.7 : 264.3, 10.0 : 4.0
0.456, 0.714
3.637
0.056
C
A
0.319
158.7 : 327.3, 1.0 : 13.0
0.327, 0.071
4.084
0.043
A
A
0.215
104.3 : 381.7, 3.0 : 11.0
0.215, 0.215
0
0.999A haplotype analysis was also performed between patients in the 1-9 years and 10 years and older age groups. One single haplotype was statistically significant (Table9). The haplotype C-A of rs2046068 and rs2227491 was elevated in the 10 years and older age group compared with the 1-9 years age group (frequency 31.9%, P=0.041).Table 9
Haplotypes of IL-22 gene when group 1-9 years of age was compared to 10 years and above.
Haplotype
Freq.
Case, control ratio counts
Case, control frequencies
Chi square
P value
rs2046068
rs2227491
A
G
0.463
209.7 : 254.3, 22.0 : 14.0
0.452, 0.611
3.378
0.066
C
A
0.319
153.7 : 310.3, 6.0 : 30.0
0.331, 0.166
4.193
0.041
A
A
0.215
99.3 : 364.7, 8.0 : 28.0
0.214, 0.223
0.015
0.901Finally, we assessed the haplotype distribution between patients in the 1-9 years and 41 years and older age groups. The distribution of two haplotypes was significantly different in these two groups (Table10). The haplotype C-A of rs2046068 and rs2227491 was higher in 41 years and older age group (frequency 29.9%, P=0.045).Table 10
Haplotypes of IL-22 gene when group 1-9 years of age was compared to 41 years and above.
Haplotype
Freq.
Case, control ratio counts
Case, control frequencies
Chi Square
P value
rs2046068
rs2227491
A
G
0.472
46.0 : 62.0, 22.0 : 14.0
0.426, 0.611
3.715
0.053
C
A
0.299
37.0 : 71.0, 6.0 : 30.0
0.343, 0.167
3.99
0.045
A
A
0.229
25.0 : 83.0, 8.0 : 28.0
0.231, 0.222
0.013
0.908


### 3.7. Functional Analysis of the SNPs Located in the IL-22 Promoter

For the delineation of the molecular mechanisms driving the IL-22 gene, nested deletions from the IL-22 promoter were generated (Figure1(a)) and cloned in a luciferase expression system. The clones were transfected in the HEK293 cell line for 48 hours. Cells were harvested and tested for mean luciferase activity. As demonstrated in Figure 1(a), construct F3R1 containing IL-22 variant rs2227513 showed maximum luciferase activity.Figure 1
Luciferase activity assay for fragments containing the promoter ofIL-22 gene. (a) Nested deletions of the promoter region were generated and cloned. The clones were then transfected in HEK293 cell line for 48 h. Cells were harvested and tested for luciferase activity. (b) Two constructs of fragment F3R1 containing SNP rs2227513 were generated. One clone harbored A allele and the other clone contained G allele of SNP rs2227513. Luciferase activity was performed as shown in (a).
(a)
(b)To test whether rs2227513 contributes to the expression of the IL-22, one nucleotide was changed in clone F3/R1 (Figure1(b)). The IL-22 promoter activity of the variant rs2227513 alleles A and G was measured. The findings indicated that the HEK293 cells transfected with variant rs2227513 G allele had statistically significant higher luciferase activity compared to the A allele (P<0.0001).


## 3.1. The Association of the IL-22 Genotype and Allele Distribution and Risk of P. falciparum Malaria

The genotype distribution of the SNPs in the IL-22 gene between theP. falciparum-infected group and control group was investigated. The frequency of the TT genotype of rs2227481 was significantly higher in the control group compared to the malaria group (8.5% versus 2.4%, OR=0.254; 95% CI 0.097-0.663, χ2=8.9, and P=0.002) (Table 1). In addition, the T allele at variant rs2227481 was statistically higher in the control compared to the malaria group (allele frequency 22.7% versus 16.2%, OR=0.656; 95% CI 0.470-0.916, χ2=6.17, and P=0.013). We also found that the T allele was associated with a lower risk of P. falciparum malaria in a recessive model (OR=0.265; 95% CI 0.102–0.685, χ2=8.52, and P=0.003). For IL-22 variant rs2227483, we identified that the heterozygous AT genotype frequency was significantly higher in the control group in comparison to the patient group (genotype frequency 13% versus 5.2%, OR=0.375; 95% CI 0.187-0.754, χ2=8.05, and P=0.004).Table 1
Genotype distribution and allele frequency of IL-22 SNPs among malaria patients compared to healthy control subjects.
SNPs
Genotype/allele distribution
Control
Patients
OR (95% CI)
χ2
P value
rs976748
TT
193 (96.5%)
236 (94.4%)
Ref
CT
6 (3%)
13 (5.2%)
1.772 (0.661-4.749)
1.33
0.249
CC
1 (0.5%)
1 (0.4%)
0.818 (0.051-13.160)
0.02
0.886
T
392 (98%)
485 (97%)
1.515 (0.636-3.611)
0.89
0.344
C
8 (2%)
15 (3%)
CC+CT vs. TT
1.636 (0.647-4.133)
1.1
0.293
CC vs. CT+TT
1.251 (0.078-20.130)
0.03
0.874
rs1179246
CC
55 (27.5%)
86 (34.4%)
Ref
AC
98 (49%)
112 (44.8%)
0.731 (0.474-1.128)
2.01
0.155
AA
47 (23.5%)
52 (20.8%)
0.708 (0.421-1.190)
1.71
0.191
C
208 (52%)
284 (56.8%)
0.824 (0.633-1.073)
2.07
0.150
A
192 (48%)
216 (43.2%)
AA+AC vs. CC
0.723 (0.482-1.085)
2.46
0.116
AA vs. AC+CC
0.855 (0.547-1.338)
0.47
0.492
rs2046068
AA
104 (52%)
114 (45.6%)
Ref
AC
76 (38%)
111 (44.4%)
1.332 (0.898-1.977)
2.03
0.153
CC
20 (10%)
25 (10%)
1.140 (0.598-2.174)
0.16
0.689
A
284 (71%)
339 (67.8%)
1.163 (0.873-1.548)
1.07
0.301
C
116 (29%)
161 (32.2%)
CC+AC vs. AA
1.292 (0.890-1.876)
1.82
0.177
CC vs. AC+AA
1.000 (0.538-1.859)
0
1
rs1182844
TT
83 (41.5%)
90 (36%)
Ref
AT
95 (47.5%)
120 (48%)
1.165 (0.779-1.741)
0.55
0.456
AA
22 (11%)
40 (16%)
1.677 (0.921-3.054)
2.88
0.089
T
261 (65.3%)
300 (60%)
1.252 (0.953-1.644)
2.61
0.106
A
139 (34.5%)
200 (40%)
AA+AT vs. TT
1.261 (0.861-1.848)
1.42
0.233
AA vs. AT+TT
1.541 (0.883-2.690)
2.34
0.126
rs2227508
AA
140 (70)
166 (66.4%)
Ref
AT
56 (28)
71 (28.4%)
1.069 (0.705-1.621)
0.1
0.752
TT
4 (2)
13 (5.2%)
2.741 (0.874-8.596)
3.22
0.072
A
336 (84)
403 (80.6%)
1.264 (0.893-1.788)
1.75
0.186
T
64 (16)
97 (19.4%)
TT+AT vs. AA
1.181 (0.791-1.762)
0.66
0.415
TT vs. AT+AA
2.333 (0.750-7.264)
3.13
0.076
rs2227478
TT
84 (42%)
100 (40%)
Ref
CT
82 (41%)
115 (46%)
1.178 (0.785-1.767)
0.63
0.428
CC
34 (17%)
35 (14%)
0.865 (0.497-1.505)
0.26
0.606
T
250 (62.5%)
315 (63%)
0.979 (0.746-1.285)
0.02
0.877
C
150 (37.5%)
185 (37%)
CC+CT vs. TT
1.086 (0.744-1.585)
0.18
0.668
CC vs. CT+TT
0.795 (0.476-1.328)
0.77
0.380
rs2227481
CC
126 (63%)
175 (70%)
Ref
CT
57 (28.5%)
69 (27.6%)
0.872 (0.573-1.325)
0.41
0.520
TT
17 (8.5%)
6 (2.4%)
0.254(0.097-0.663)
8.9
0.002
C
309 (77.3%)
419 (83.8%)
0.656 (0.470-0.916)
6.17
0.013
T
91 (22.7%)
81 (16.2%)
TT+CT vs. CC
0.730 (0.492-1.083)
2.46
0.116
TT vs. CT+CC
0.265 (0.102-0.685)
8.52
0.003
rs2227491
AA
60 (30%)
72 (28.8%)
Ref
AG
83 (41.5%)
123 (49.2%)
1.235 (0.794-1.920)
0.88
0.348
GG
57 (28.5%)
55 (22%)
0.804 (0.485-1.332)
0.72
0.396
A
203 (50.8%)
267 (53.4%)
0.899 (0.691-1.170)
0.63
0.429
G
197 (49.2%)
233 (46.6%)
GG+AG vs. AA
1.060 (0.705-1.593)
0.08
0.781
GG vs. AG+AA
0.708 (0.461-1.086)
2.51
0.113
rs2227483
TT
153 (76.5%)
204 (81.6%)
Ref
AT
26 (13%)
13 (5.2%)
0.375 (0.187-0.754)
8.05
0.004
AA
21 (10.5%)
33 (13.2%)
1.179 (0.656-2.117)
0.3
0.582
T
332 (83%)
421 (84.2%)
0.916 (0.643-1.306)
0.23
0.628
A
68 (17%)
79 (15.8%)
AA+AT vs. TT
0.734 (0.465-1.160)
1.76
0.184
AA vs. AT+TT
1.296 (0.724-2.319)
0.77
0.381


## 3.2. The Association of the IL-22 Genotype and Allele Distribution and Risk of Advanced P. falciparum Malaria Based on Parasite Density

The malaria group was classified into four cohorts depicting low to high parasite density: I, II, III, and IV. The rs2227481 CT genotype was significantly higher in cohort IV than in cohorts I+II+III and associated with a higher risk of the more severe form of the disease (genotype frequency 33.1% versus 17.8%,OR=2.208; 95% CI 1.170-4.170, χ2=6.13, and P=0.013) (Table 2). In addition, the T allele was associated with a higher vulnerability to develop advanced P. falciparum malaria infection in a dominant model (OR=1.833; 95% CI 1.012-3.322, χ2=4.05, and P=0.044). The IL-22 SNPs were examined in cohort I compared to cohort II+III+IV and cohort I+II compared to cohorts III+IV; however, none of the SNPs showed any statistically significant distribution between the groups (Supplementary Tables 4 and 5).Table 2
Genotype distribution and allele frequency of IL-22 SNPs in group I+II+III of parasite density compared to group IV.
SNPs
Genotype/allele distribution
Group I+II+III
Group IV
OR (95% CI)
χ2
P value
rs976748
TT
86 (95.6%)
150 (93.8%)
Ref
CT
4 (4.4%)
9 (5.6%)
1.290 (0.386-4.314)
0.17
0.678
CC
0 (0%)
1 (0.6%)
1.724 (0.069-42.790)
0.57
0.449
T
176 (97.8%)
309 (96.6%)
1.566 (0.491-4.993)
0.58
0.444
C
4 (2.2%)
11 (3.4%)
CC+CT vs. TT
1.433 (0.436-4.709)
0.36
0.551
CC vs. CT+TT
0.587 (0.024-14.571)
0.56
0.452
rs1179246
CC
28 (31.1%)
57 (35.6%)
Ref
AC
43 (47.8%)
69 (43.1%)
0.788 (0.436-1.424)
0.62
0.429
AA
19 (21.1%)
34 (21.3%)
0.879 (0.427-1.808)
0.12
0.725
C
99 (55%)
183 (57.2%)
0.915 (0.633-1.322)
0.22
0.635
A
81 (45%)
137 (42.8%)
AA+AC vs. CC
0.816 (0.470-1.416)
0.52
0.469
AA vs. AC+CC
1.008 (0.536-1.898)
0
0.979
rs2046068
AA
39 (43.3%)
75 (46.9%)
Ref
AC
44 (48.9%)
67 (41.9%)
0.792 (0.460-1.362)
0.71
0.398
CC
7 (7.8%)
18 (11.2%)
1.337 (0.515-3.475)
0.36
0.550
A
122 (67.8%)
217 (67.8%)
0.998 (0.675-1.476)
0
0.993
C
58 (32.2%)
103 (32.2%)
CC+AC vs. AA
0.867 (0.515-1.458)
0.29
0.589
CC vs. AC+AA
1.503 (0.603-3.749)
0.77
0.379
rs1182844
TT
27 (30%)
63 (39.4%)
Ref
AT
46 (51.1%)
74 (46.2%)
0.689(0.385-1.234)
1.57
0.209
AA
17 (18.9%)
23 (14.4%)
0.580 (0.268-1.255)
1.93
0.164
T
100 (55.6%)
200 (62.5%)
0.750 (0.518-1.087)
2.31
0.128
A
80 (44.4%)
120 (37.5%)
AA+AT vs. TT
0.660 (0.380-1.145)
2.2
0.138
AA vs. AT+TT
0.721 (0.362-1.435)
0.87
0.350
rs2227508
AA
57 (63.3%)
109 (68.1%)
Ref
AT
26 (28.9%)
45 (28.1%)
0.905 (0.507-1.616)
0.11
0.735
TT
7 (7.8%)
6 (3.8%)
0.448 (0.144-1.397)
2
0.157
A
140 (77.8%)
263 (82.2%)
0.759 (0.482-1.194)
1.43
0.231
T
40 (22.2%)
57 (17.8%)
TT+AT vs. AA
0.808 (0.470-1.390)
0.59
0.441
TT vs. AT+AA
0.462 (0.150-1.420)
1.9
0.168
rs2227478
TT
35 (38.9%)
65 (40.6%)
Ref
CT
38 (42.2%)
77 (48.1%)
1.091 (0.620-1.921)
0.09
0.762
CC
17 (18.9%)
18 (11.3%)
0.570(0.261-1.244)
2.02
0.155
T
108 (60%)
207 (64.7%)
0.819 (0.562-1.193)
1.09
0.297
C
72 (40%)
113 (35.3%)
CC+CT vs. TT
0.930 (0.548-1.577)
0.07
0.787
CC vs. CT+TT
0.544 (0.265-1.119)
2.79
0.094
rs2227481
CC
70 (77.8%)
105 (65.6%)
Ref
CT
16 (17.8%)
53 (33.1%)
2.208 (1.170-4.170)
6.13
0.013
TT
4 (4.4%)
2 (1.3%)
0.333 (0.059-1.869)
1.71
0.191
C
156 (86.7%)
263 (82.2%)
1.409 (0.841-2.361)
1.7
0.191
T
24 (13.3%)
57 (17.8%)
TT+CT vs. CC
1.833 (1.012-3.322)
4.05
0.044
TT vs. CT+CC
0.272 (0.0488-1.516)
2.51
0.113
rs2227491
AA
24 (26.7%)
48 (30%)
Ref
AG
49 (54.4%)
74 (46.2%)
0.755 (0.411-1.388)
0.82
0.365
GG
17 (18.9%)
38 (23.8%)
1.118 (0526-2.373)
0.08
0.772
A
97 (53.9%)
170 (53.1%)
1.031 (0.715-1.487)
0.03
0.869
G
83 (46.1%)
150 (46.9%)
GG+AG vs. AA
0.848 (0.477-1.510)
0.31
0.576
GG vs. AG+AA
1.338 (0.704-2.540)
0.79
0.373
rs2227483
TT
73 (81.1%)
131 (81.9%)
Ref
AT
4 (4.4%)
9 (5.6%)
1.254 (0.373-4.213)
0.13
0.714
AA
13 (14.5%)
20 (12.5%)
0.857 (0.403-1.823)
0.16
0.689
T
150 (83.3%)
271 (84.7%)
0.904 (0.550-1.485)
0.16
0.690
A
30 (16.7%)
49 (15.3%)
AA+AT vs. TT
0.951 (0.490-1.846)
0.02
0.881
AA vs. AT+TT
0.846 (0.399-1.794)
0.19
0.662


## 3.3. The Association of the IL-22 Genotype and Allele Distribution Based on the Age of Infected Patients

A comparison of the malaria group in the 1-5 year age group with the 6 years and older age group indicated that the frequency of the rs2046068 A allele was statistically lower in the 6 years and older group (67% versus 92.9%,OR=6.380; 95% CI 0.827-49.203, χ2=4.14, and P=0.044). Also, the rs2046068 A allele was significant in a dominant model (OR=7.5; 95% CI 0.889-63.242, χ2=4.67, and P=0.030) (Table 3).Table 3
Genotype distribution and allele frequency of IL-22 SNPs in group 1-5 years of age compared to 6 years and above age group.
SNPs
Genotype/allele distribution
1-5 years
6 years and above
OR (95% CI)
χ2
P value
rs976748
TT
7 (100%)
229 (94.3%)
Ref
CT
0 (0%)
13 (5.3%)
0.882 (0.048-16.276)
0.4
0.528
CC
0 (0%)
1 (0.4%)
0.098 (0.004-2.611)
0.03
0.861
T
14 (100%)
471 (97%)
0.953 (0.054-16.717)
0.45
1
C
0 (0%)
15 (3%)
CC+CT vs. TT
0.948 (0.052-17.423)
0.43
0.513
CC vs. CT+TT
0.093 (0.004-2.471)
0.03
0.864
rs1179246
CC
2 (28.6%)
85 (35%)
Ref
AC
5 (71.4%)
107 (44%)
0.504 (0.095-2.660)
0.68
0.410
AA
0 (0%)
51 (21%)
3.012 (0.142-63.975)
1.19
0.275
C
9 (64.3%)
277 (57%)
1.358 (0.449-4.112)
0.3
0.586
A
5 (35.7%)
209 (43%)
AA+AC vs. CC
0.744 (0.141-3.914)
0.12
0.725
AA vs. AC+CC
4.013 (0.225-71.433)
1.85
0.174
rs2046068
AA
6 (85.7%)
108 (44.4%)
Ref
AC
1 (14.3%)
110 (45.3%)
6.111 (0.724-51.609)
3.55
0.059
CC
0 (0%)
25 (10.3%)
3.055 (0.167-56.007)
1.38
0.240
A
13 (92.9%)
326 (67%)
6.380 (0.827-49.203)
4.14
0.044
C
1 (7.1%)
160 (33%)
CC+AC vs. AA
7.500(0.889-63.242)
4.67
0.030
CC vs. AC+AA
1.751 (0.097-31.562)
0.8
0.371
rs1182844
TT
3 (42.9%)
87 (35.8%)
Ref
AT
4 (57.1%)
116 (47.7%)
1.00 (0.218-4.584)
0
1
AA
0 (0%)
40 (16.5%)
3.240 (0.164-64.205)
1.36
0.242
T
10 (71.4%)
290 (59.7%)
1.690 (0.523-5.464)
0.78
0.375
A
4 (28.6%)
196 (40.3%)
AA+AT vs. TT
1.345 (0.294-6.147)
0.15
0.701
AA vs. AT+TT
2.985 (0.167-53.317)
1.37
0.241
rs2227508
AA
6 (85.7%)
160 (65.8%)
Ref
AT
1 (14.3%)
70 (28.8%)
2.625 (0.310-22.212)
0.84
0.358
TT
0 (0%)
13 (5.4%)
1.093 (0.058-20.469)
0.49
0.485
A
13 (92.9%)
390 (80.2%)
3.200 (0.414-24.762)
1.38
0.323
T
1 (7.1%)
96 (19.8%)
TT+AT vs. AA
3.112 (0.369-26.284)
1.2
0.272
TT vs. AT+AA
0.879 (0.047-16.206)
0.4
0.529
rs2227478
TT
5 (71.4%)
95 (39.1%)
Ref
CT
2 (28.6%)
113 (46.5%)
2.974 (0.564-15.677)
1.81
0.179
CC
0 (0%)
35 (14.4%)
4.089 (0.220-75.860)
1.82
0.177
T
12 (85.7%)
303 (62.3%)
3.624 (0.802-16.374)
3.19
0.074
C
2 (14.3%)
183 (37.7%)
CC+CT vs. TT
3.895 (0.741-20.482)
2.96
0.085
CC vs. CT+TT
2.554 (0.143-45.516)
1.17
0.278
rs2227481
CC
6 (85.7%)
169 (69.5%)
Ref
CT
1 (14.3%)
68 (28%)
2.414 (0.285-20.430)
0.7
0.404
TT
0 (0%)
6 (2.5%)
0.499 (0.025-9.827)
0.21
0.644
C
13 (92.9%)
406 (83.5%)
2.562 (0.330-19.859)
0.87
0.710
T
1 (7.1%)
80 (16.5%)
TT+CT vs. CC
2.627 (0.311-22.209)
0.85
0.357
TT vs. CT+CC
0.411 (0.0211-7.977)
0.18
0.673
rs2227491
AA
3 (42.9%)
72 (29.6%)
Ref
AG
4 (57.1%)
119 (49%)
1.240 (0.270-5.698)
0.08
0.782
GG
0 (0%)
52 (21.4%)
5.069 (0.256-100.237)
2.13
0.144
A
10 (71.4%)
263 (54.1%)
2.120 (0.656-6.852)
1.65
0.199
G
4 (28.6%)
223 (45.9%)
GG+AG vs. AA
1.781 (0.389-8.161)
0.57
0.451
GG vs. AG+AA
4.112 (0.231-73.184)
1.89
0.169
rs2227483
TT
5 (71.4%)
199 (81.9%)
Ref
AT
0 (0%)
13 (5.3%)
0.744 (0.039-14.180)
0.33
0.567
AA
2 (28.6%)
31 (12.8%)
0.389 (0.072-2.096)
1.29
0.255
T
10 (71.4%)
411 (84.6%)
0.456 (0.139-1.493)
1.77
0.252
A
4 (28.6%)
75 (15.4%)
AA+AT vs. TT
0.553 (0.104-2.942)
0.5
0.481
AA vs. AT+TT
0.365 (0.068-1.966)
1.49
0.222Comparing the malaria group in a 1-9 years age group with a 10 years and older age group, the frequency of the rs976748 CT genotype was significantly higher in the 1-9 years age group compared to the other group (genotype frequency 16.7% versus 4.3%,OR=0.226; 95% CI 0.056-0.910, χ2=5.14, and P=0.023) (Table 4). Under a dominant mode of inheritance, rs976748 was associated with a higher risk of P. falciparum malaria infection in the 10 years and older age group (OR=0.249; 95% CI 0.063-0.989, χ2=4.49, and P=0.034). The rs2227478 CT genotype was substantially elevated in the 10 years and older age group malaria compared to the younger age group (genotype frequency 47.8% versus 22.2%, OR=3.430; 95% CI 1.056-11.138, χ2=4.66, and P=0.030) (Table 4). Similarly, the A allele of SNP rs2046068 was more frequent in the 1-9 years age group (83.3% versus 66.6%, OR=2.508; 95% CI 1.022-6.154, χ2=4.29, and P=0.038), with the T allele of rs2227483 associated with the 10 years and older age group (85.3% versus 69.4%, OR=0.390; 95% CI 0.184-0.830, χ2=6.35, and P=0.011).Table 4
Genotype distribution and allele frequency of IL-22 SNPs in group 1-9 years of age compared to 10 years and above age group.
SNPs
Genotype/allele distribution
1-9 years
10 years and above
OR (95% CI)
χ2
P value
rs976748
TT
15 (83.3%)
221 (95.3%)
Ref
CT
3 (16.7%)
10 (4.3%)
0.226 (0.056-0.910)
5.14
0.023
CC
0 (0%)
1 (0.4%)
0.210 (0.008-5.370)
0.07
0.794
T
33 (91.7%)
452 (97.4%)
0.292 (0.079-1.086)
3.79
0.085
C
3 (8.3%)
12 (2.6%)
CC+CT vs. TT
0.249 (0.063-0.989)
4.49
0.034
CC vs. CT+TT
0.240 (0.009-6.094)
0.08
0.780
rs1179246
CC
5 (27.8%)
80 (34.5%)
Ref
AC
8 (44.4%)
104 (44.8%)
0.812 (0.256-2.578)
0.12
0.724
AA
5 (27.8%)
48 (20.7%)
0.600 (0.165-2.180)
0.61
0.433
C
18 (50%)
264 (56.9%)
0.758 (0.384-1.493)
0.65
0.421
A
18 (50%)
200 (43.1%)
AA+AC vs. CC
0.731 (0.252-2.123)
0.33
0.562
AA vs. AC+CC
10.678 (0.231-1.996)
0.5
0.478
rs2046068
AA
12 (66.7%)
102 (44%)
Ref
AC
6 (33.3%)
105 (45.3%)
2.059 (0.745-5.693)
2
0.156
CC
0 (0%)
25 (10.7%)
6.220 (0.356-108.579)
2.88
0.089
A
30 (83.3%)
309 (66.6%)
2.508 (1.022-6.154)
4.29
0.038
C
6 (16.7%)
155 (33.4%)
CC+AC vs. AA
2.549(0.925-7.024)
3.47
0.062
CC vs. AC+AA
4.547 (0.266-77.748)
2.16
0.142
rs1182844
TT
7 (38.9%)
83 (35.8%)
Ref
AT
11 (61.1%)
109 (41%)
0.836 (0.311-2.248)
0.13
0.721
AA
0 (0%)
40 (17.2%)
7.275 (0.405-130.544)
3.29
0.069
T
25 (69.4%)
275 (59.3%)
1.562 (0.751-3.251)
1.44
0.229
A
11 (30.6%)
189 (40.7%)
AA+AT vs. TT
1.142 (0.427-3.059)
0.07
0.790
AA vs. AT+TT
7.784 (0.459-131.835)
3.69
0.054
rs2227508
AA
14 (77.8%)
152 (65.5%)
Ref
AT
4 (22.2%)
67 (28.9%)
1.543 (0.490-4.861)
0.56
0.456
TT
0 (0%)
13 (5.6%)
2.567 (0.145-45.441)
1.19
0.275
A
32 (88.9%)
371 (80%)
2.005 (0.692-5.811)
1.7
0.191
T
4 (11.1%)
93 (20%)
TT+AT vs. AA
1.842 (0.587-5.781)
1.13
0.288
TT vs. AT+AA
2.276 (0.130-39.829)
1.06
0.302
rs2227478
TT
11 (61.1%)
89 (38.4%)
Ref
CT
4 (22.2%)
111 (47.8%)
3.430 (1.056-11.138)
4.66
0.030
CC
3 (16.7%)
32 (13.8%)
1.318 (0.346-5.030)
0.16
0.685
T
26 (72.2%)
289 (62.3%)
1.574 (0.741-3.343)
1.42
0.234
C
10 (27.8%)
175 (37.7%)
CC+CT vs. TT
2.525 (0.944-6.754)
3.6
0.057
CC vs. CT+TT
0.800 (0.219-2.919)
0.11
0.735
rs2227481
CC
13 (72.2%)
162 (69.8%)
Ref
CT
4 (22.2%)
65 (28%)
1.304 (0.410-4.147)
0.2
0.652
TT
1 (5.6%)
5 (2.2%)
0.401 (0.044-3.695)
0.69
0.404
C
30 (83.3%)
389 (83.8%)
0.964(0.388-2.397)
0.01
0.937
T
6 (16.7%)
75 (16.2%)
TT+CT vs. CC
1.123 (0.386-3.271)
0.05
0.830
TT vs. CT+CC
0.374 (0.041-3.389)
0.82
0.363
rs2227491
AA
5 (27.7%)
71 (30.6%)
Ref
AG
12 (66.7%)
111 (47.8%)
0.651 (0.220-1.928)
0.61
0.435
GG
1 (5.6%)
50 (21.6%)
3.52 (0.399-31.065)
1.45
0.229
A
22 (61.1%)
253 (54.5%)
1.311 (0.654-2.625)
0.59
0.444
G
14 (38.9%)
211 (45.5%)
GG+AG vs. AA
0.872(0.300-2.539)
0.06
0.801
GG vs. AG+AA
4.670 (0.607-35.952)
2.63
0.104
rs2227483
TT
12 (66.7%)
192 (82.8%)
Ref
AT
1 (5.6%)
12 (5.2%)
0.750 (0.090-6.259)
0.07
0.789
AA
5 (27.7%)
28 (12%)
0.350 (0.115-1.068)
3.67
0.055
T
25 (69.4%)
396 (85.3%)
0.390 (0.184-0.830)
6.35
0.011
A
11 (30.6%)
68 (14.7%)
AA+AT vs. TT
0.417 (0.148-1.176)
2.88
0.089
AA vs. AT+TT
0.357 (0.118-1.077)
3.6
0.057No relationship was observed between the IL-22 SNPs and the risk ofP. falciparum malaria comparing the malaria group in the 10-20 years age group with the 21 years and older group (Supplementary Table 6). Finally, we investigated whether the IL-22 gene SNPs significantly differed in frequency between the P. falciparum malaria group, 1-9 years age group, and 41 years and older age group (Table 5). We found that the IL-22 rs2046068 A allele was significantly associated with a higher risk of P. falciparum malaria in the 1-9 years age group. In addition, the A allele of rs2046068 was statistically higher in the 1-9 years age group compared to the 41 years and older age group (allele frequency 83.3% versus 65.7%, OR=2.606; 95% CI 0.995-6.821, χ2=3.99, and P=0.045). No dominant or recessive statistically significant relationship was observed between the two groups. In contrast, the IL-22 rs2227483 T allele was associated with a high susceptibility to develop P. falciparum malaria in the 41 years and older age group with a higher frequency of the rs2227483 T allele (allele frequency 86.1% versus 69.4%, OR=0.367; 95% CI 0.150-0.897, χ2=5.07, and P=0.024). For both SNPs, no dominant or recessive relationship was detected.Table 5
Genotype distribution and allele frequency of IL-22 SNPs in group 1-9 years of age compared to 41 years and above age group.
SNPs
Genotype/allele distribution
1-9 years
41 years and above
OR (95% CI)
χ2
P value
rs976748
TT
15 (83.3%)
49 (90.7%)
Ref
CT
3 (16.7%)
5 (9.3%)
0.510 (0.109-2.389)
0.75
0.386
CC
0 (0%)
0 (0%)
0.313 (0.006-16.446)
Nan
1
T
33 (91.7%)
103 (95.4%)
0.534 (0.121-2.355)
0.71
0.412
C
3 (8.3%)
5 (4.6%)
CC+CT vs. TT
0.510 (0.109-2.389)
0.75
0.386
CC vs. CT+TT
0.339 (0.007-17.723)
Nan
1
rs1179246
CC
5 (27.8%)
25 (46.3%)
Ref
AC
8 (44.4%)
16 (29.6%)
0.400 (0.111-1.441)
2.03
0.154
AA
5 (27.8%)
13 (24.1%)
0.520 (0.127-2.128)
0.84
0.358
C
18 (50%)
66 (61.1%)
0.636 (0.298-1.360)
1.37
0.241
A
18 (50%)
42 (38.9%)
AA+AC vs. CC
0.446 (0.140-1.426)
1.9
0.167
AA vs. AC+CC
0.824 (0.247-2.752)
0.1
0.753
rs2046068
AA
12 (66.7%)
25 (46.3%)
Ref
AC
6 (33.3%)
21 (38.9%)
1.680 (0.538-5.247)
0.8
0.369
CC
0 (0%)
8 (14.8%)
8.333 (0.444-156.275)
3.54
0.059
A
30 (83.3%)
71 (65.7%)
2.606 (0.995-6.821)
3.99
0.045
C
6 (16.7%)
37 (34.3%)
CC+AC vs. AA
2.320(0.760-7.085)
2.24
0.134
CC vs. AC+AA
6.763 (0.371-123.24)
3
0.083
rs1182844
TT
7 (38.9%)
20 (37%)
Ref
AT
11 (61.1%)
22 (40.7%)
0.700 (0.227-2.155)
0.39
0.533
AA
0 (0%)
12 (22.2%)
9.146 (0.480-174.374)
3.79
0.051
T
25 (69.4%)
62 (57.4%)
1.686 (0.754-3.772)
1.64
0.200
A
11 (30.6%)
46 (42.6%)
AA+AT vs. TT
1.082 (0.361-3.240)
0.02
0.888
AA vs. AT+TT
10.882 (0.612-193.665)
4.8
0.028
rs2227508
AA
14 (77.8%)
36 (66.7%)
Ref
AT
4 (22.2%)
14 (25.9%)
1.361 (0.382-4.852)
0.23
0.633
TT
0 (0%)
4 (7.4%)
3.757 (0.181-70.702)
1.51
0.218
A
32 (88.9%)
86 (79.6%)
2.047 (0.654-6.399)
1.56
0.211
T
4 (11.1%)
22 (20.4%)
TT+AT vs. AA
1.750 (0.503-6.089)
0.79
0.375
TT vs. AT+AA
3.297 (0.169-64.262)
1.41
0.234
rs2227478
TT
11 (61.1%)
24 (44.4%)
Ref
CT
4 (22.2%)
20 (37%)
2.292 (0.631-8.317)
1.64
0.200
CC
3 (16.7%)
10 (18.5%)
1.528 (0.350-6.674)
0.32
0.571
T
26 (72.2%)
68 (63%)
1.529(0.669-3.498)
1.02
0.312
C
10 (27.8%)
40 (37%)
CC+CT vs. TT
1.964 (0.661-5.837)
1.5
0.220
CC vs. CT+TT
1.136 (0.276-4.688)
0.03
0.859
rs2227481
CC
13 (72.2%)
38 (70.4%)
Ref
CT
4 (22.2%)
13 (24.1%)
1.112 (0.307-4.021)
0.03
0.871
TT
1 (5.6%)
3 (5.5%)
1.026 (0.098-10.752)
0
0.982
C
30 (83.3%)
89 (82.4%)
1.067 (0.390-2.921)
0.02
0.898
T
6 (16.7%)
19 (17.6%)
TT+CT vs. CC
1.095 (0.335-3.582)
0.02
0.881
TT vs. CT+CC
1.00 (0.097-10.265)
0
1
rs2227491
AA
5 (27.7%)
20 (37%)
Ref
AG
12 (66.7%)
22 (40.7%)
0.458 (0.137-1.531)
1.64
0.199
GG
1 (5.6%)
12 (22.2%)
3 (0.312-28.841)
0.97
0.336
A
22 (61.1%)
62 (57.4%)
1.166 (0.539-2.521)
0.15
0.696
G
14 (38.9%)
46 (42.6%)
GG+AG vs. AA
0.6654 (0.203-2.107)
0.51
0.474
GG vs. AG+AA
4.857 (0.585-40.32)
2.53
0.111
rs2227483
TT
12 (66.7%)
46 (85.2%)
Ref
AT
1 (5.6%)
1 (1.9%)
0.261 (0.015-4.481)
0.98
0.322
AA
5 (27.7%)
7 (12.9%)
0.365(0.098-1.356)
2.38
0.122
T
25 (69.4%)
93 (86.1%)
0.367 (0.150-0.897)
5.07
0.024
A
11 (30.6%)
15 (13.9%)
AA+AT vs. TT
0.348 (0.101-1.195)
2.96
0.085
AA vs. AT+TT
0.387 (0.105-1.423)
2.13
0.144


## 3.4. The Association of the IL-22 Haplotype and Risk of P. falciparum-Associated Malaria

A haplotype analysis was done between theP. falciparum-infected group and the control group and two blocks were generated. Block 1 comprised the IL-22 polymorphisms rs1179246, rs1182844, and rs976748, with block 2 consisting of IL-22 polymorphisms rs2046068 and rs2227491 (Table 6). One haplotype in block 1 was statistically significant. The haplotype A-T-T involving the alleles of rs1179246, rs1182844, and rs976748 was statistically more frequent in the control group than the malaria group (frequency 41%, P=0.034). In block 2, one haplotype A-G of rs2046068 and rs2227491 was statistically significant and prevalent in the control group but not in the malaria group (Frequency 49.4%, P=0.041).Table 6
Haplotypes of IL-22 gene when control group was compared to patients’ group.
Haplotype (block 1)
Freq.
Case, control ratio counts
Case, control frequencies
Chi square
P value
rs1179246
rs1182844
rs976748
A
T
T
0.41
189.3 : 310.7, 179.3 : 220.7
0.379, 0.448
4.465
0.034
C
A
T
0.356
186.3 : 313.7, 134.3 : 265.7
0.373, 0.336
1.312
0.252
C
T
T
0.188
95.7 : 404.3, 73.7 : 326.3
0.191, 0.184
0.075
0.783
A
T
C
0.026
15.0 : 485.0, 8.0 : 392.0
0.030, 0.020
0.892
0.344
A
A
T
0.02
13.7 : 486.3, 4.7 : 395.3
0.027, 0.012
2.733
0.098
Haplotype (block 2)
rs2046068
rs2227491
A
G
0.494
231.9 : 268.1, 212.9 : 187.1
0.464, 0.532
4.174
0.041
C
A
0.306
159.9 : 340.1, 115.9 : 284.1
0.320, 0.290
0.94
0.332
A
A
0.198
107.1 : 392.9, 71.1 : 328.9
0.214, 0.178
1.866
0.171


## 3.5. The Association of the IL-22 Haplotype and Risk of Advanced P. falciparum Malaria Based on Parasite Density

A haplotype analysis was performed between cohort I+II and cohort III+IV of varied parasite density (Table7). The distribution of only one haplotype was found to be significantly different in the groups. The haplotype C-A-C-A-C-C including alleles of rs1179246, rs1182844, rs2046068, rs2227491, rs2227481, and rs2227478 occurred more frequently in cohort I+II (frequency 13.7%, P=0.036).Table 7
Haplotypes of IL-22 gene when group I+II of parasite density was compared to group III+IV.
Haplotypes
Freq.
Case, control ratio counts
Case, control frequencies
Chi square
P value
rs1179246
rs1182844
rs2046068
rs2227491
rs2227481
rs2227478
A
T
A
G
C
T
0.374
158.1 : 265.9, 28.7 : 47.3
0.373, 0.378
0.007
0.933
C
A
A
A
C
T
0.145
63.9 : 360.1, 8.6 : 67.4
0.151, 0.113
0.732
0.392
C
A
C
A
C
C
0.137
52.3 : 371.7, 16.2 : 59.8
0.123, 0.213
4.386
0.036
C
T
C
A
T
C
0.1
44.8 : 379.2, 5.2 : 70.8
0.106, 0.069
0.959
0.327
C
A
A
A
C
C
0.038
16.9 : 407.1, 2.3 : 73.7
0.040, 0.030
0.178
0.672
C
A
C
A
C
T
0.032
15.9 : 408.1, 0.2 : 75.8
0.037, 0.003
2.457
0.117
C
T
C
A
C
C
0.017
6.6 : 417.4, 1.9 : 74.1
0.016, 0.025
0.323
0.569
C
T
A
G
C
T
0.017
6.8 : 417.2, 1.4 : 74.6
0.016, 0.019
0.024
0.877
A
T
A
G
C
C
0.016
6.9 : 417.1, 1.3 : 74.7
0.016, 0.017
0.003
0.955
C
T
A
G
C
C
0.015
7.4 : 416.6, 0.0 : 76.0
0.018, 0.000
1.312
0.252
C
T
A
G
T
C
0.014
7.1 : 416.9, 0.0 : 76.0
0.017, 0.000
1.292
0.255
C
T
A
G
C
C
0.013
4.5 : 419.5, 1.7 : 74.3
0.011, 0.023
0.778
0.377
A
A
C
A
C
C
0.012
5.8 : 418.2, 0.1 : 75.9
0.014, 0.001
0.869
0.351


## 3.6. The Association of the IL-22 Haplotype and Risk of Malaria Based on Age Groups

A haplotype distribution analysis was done in the malaria group for two age groups, 1-5 years and 6 years and older. The frequency of two haplotypes was found to be either statistically significant or close to significance (Table8). The haplotype A-G of rs2046068 and rs2227491 was more frequent in the 1-5 years age group (frequency 46.3%, P=0.056). However, the haplotype C-A of rs2046068 and rs2227491 was significantly high in the 6 years and older age group (frequency 31.9%, P=0.043).Table 8
Haplotypes of IL-22 gene when group 1-5 years of age was compared to 6 years and above.
Haplotypes
Freq.
Case, control ratio counts
Case, control frequencies
Chi square
P value
rs2046068
rs2227491
A
G
0.463
221.7 : 264.3, 10.0 : 4.0
0.456, 0.714
3.637
0.056
C
A
0.319
158.7 : 327.3, 1.0 : 13.0
0.327, 0.071
4.084
0.043
A
A
0.215
104.3 : 381.7, 3.0 : 11.0
0.215, 0.215
0
0.999A haplotype analysis was also performed between patients in the 1-9 years and 10 years and older age groups. One single haplotype was statistically significant (Table9). The haplotype C-A of rs2046068 and rs2227491 was elevated in the 10 years and older age group compared with the 1-9 years age group (frequency 31.9%, P=0.041).Table 9
Haplotypes of IL-22 gene when group 1-9 years of age was compared to 10 years and above.
Haplotype
Freq.
Case, control ratio counts
Case, control frequencies
Chi square
P value
rs2046068
rs2227491
A
G
0.463
209.7 : 254.3, 22.0 : 14.0
0.452, 0.611
3.378
0.066
C
A
0.319
153.7 : 310.3, 6.0 : 30.0
0.331, 0.166
4.193
0.041
A
A
0.215
99.3 : 364.7, 8.0 : 28.0
0.214, 0.223
0.015
0.901Finally, we assessed the haplotype distribution between patients in the 1-9 years and 41 years and older age groups. The distribution of two haplotypes was significantly different in these two groups (Table10). The haplotype C-A of rs2046068 and rs2227491 was higher in 41 years and older age group (frequency 29.9%, P=0.045).Table 10
Haplotypes of IL-22 gene when group 1-9 years of age was compared to 41 years and above.
Haplotype
Freq.
Case, control ratio counts
Case, control frequencies
Chi Square
P value
rs2046068
rs2227491
A
G
0.472
46.0 : 62.0, 22.0 : 14.0
0.426, 0.611
3.715
0.053
C
A
0.299
37.0 : 71.0, 6.0 : 30.0
0.343, 0.167
3.99
0.045
A
A
0.229
25.0 : 83.0, 8.0 : 28.0
0.231, 0.222
0.013
0.908


## 3.7. Functional Analysis of the SNPs Located in the IL-22 Promoter

For the delineation of the molecular mechanisms driving the IL-22 gene, nested deletions from the IL-22 promoter were generated (Figure1(a)) and cloned in a luciferase expression system. The clones were transfected in the HEK293 cell line for 48 hours. Cells were harvested and tested for mean luciferase activity. As demonstrated in Figure 1(a), construct F3R1 containing IL-22 variant rs2227513 showed maximum luciferase activity.Figure 1
Luciferase activity assay for fragments containing the promoter ofIL-22 gene. (a) Nested deletions of the promoter region were generated and cloned. The clones were then transfected in HEK293 cell line for 48 h. Cells were harvested and tested for luciferase activity. (b) Two constructs of fragment F3R1 containing SNP rs2227513 were generated. One clone harbored A allele and the other clone contained G allele of SNP rs2227513. Luciferase activity was performed as shown in (a).
(a)
(b)To test whether rs2227513 contributes to the expression of the IL-22, one nucleotide was changed in clone F3/R1 (Figure1(b)). The IL-22 promoter activity of the variant rs2227513 alleles A and G was measured. The findings indicated that the HEK293 cells transfected with variant rs2227513 G allele had statistically significant higher luciferase activity compared to the A allele (P<0.0001).


## 4. Discussion

Globally, malaria remains one of the major causes of mortality in children younger than 5 years [3]. Recently a malaria vaccine, known as RTS, S/AS01 (RTS, S), was introduced for a pilot study in three African countries, Ghana, Kenya, and Malawi. However, the vaccine is reportedly effective only against P. falciparum and has an efficacy of 39% [25]. The diverse manifestations of the disease in malaria patients drives the urgency in the search for a vaccine. It is known that there is a significant variation in the clinical symptoms associated with malaria. While some patients would die of severe malaria infection, others would have an uncomplicated infection [26]. Such disease variation suggests that in addition to the parasite and environmental influence, the genetic characteristics of the host is central in determining the clinical outcome in P. falciparum-infected patients. The understanding of genetic differences in populations substantially transformed the development of vaccines in general and assisted in developing the most recent malaria vaccine [25, 27].In this study, we examined the frequency of nine SNPs (rs976748, rs1179246, rs2046068, rs1182844, rs2227508, rs2227478, rs2227481, rs2227491, and rs2227483) in theIL-22 gene in P. falciparum malaria infection. The aim was to determine whether there is an association in terms of vulnerability or protection as indicated by the level of parasite density or the age group distribution. IL-22 is suggested to have a protective role in severe anemia-associated malaria infection, as it has been reported that IL-22 is elevated in children infected with P. falciparum [28]. Only a few studies have investigated the role of IL-22 SNPs in malaria [21, 22, 29]. The first report of the involvement of IL-22 SNPs in malaria found two IL-22 SNPs in West African children infected with P. falciparum malaria; one correlated with protection against SM (rs2227491) and the second with susceptibility to CM (rs2227478) [21]. However, both SNPs were not significant in our population for any of the tested traits. Another study in Nigerian and Malawian populations found that the T allele of two IL-22 variants, rs2227476 and rs2227473, in the promoter region is associated with CM [22]. Notably, rs2227476 is in high LD (r2=0.92) with rs2227481 and is significantly associated with the risk of P. falciparum malaria in our population. There is a dearth of data to study the role of the IL-22 gene with vulnerability or protection, parasite density and age-related risk of P. falciparum malaria infection.In the present study, we strengthen the possible relationship between theIL-22 rs2227481 T allele with protection against P. falciparum malaria infection in a recessive mode of inheritance, with a similar association found for individuals with a homozygous TT genotype. It was also found that the C allele of this SNP is associated with an increased risk of malaria infection. Our highest significant SNP (rs2227481) is in high LD with rs2227476, previously linked to a predisposition to childhood CM in an African population, potentially by altering the binding site for several transcription factors as suggested by the in silico analysis [22]. Our study supports the evidence of the role of IL-22 in the clinical manifestation of P. falciparum-associated malaria. It has been reported that the IL-22 rs2227481 polymorphism plays a crucial role in effector T cell pathways [30]. Exploring the influence of IL-22 rs2227481 on parasite density and age-related risk of malaria infection, we found that the IL-22 rs2227481 homozygous CC genotype, in a dominant mode of inheritance, is associated with a higher P. falciparum parasite density in the Saudi Arabian population. The rs2227481 T allele was associated with a low parasite density in a dominant model. However, no relationship was observed for an age-related risk of the infection. The results indicate that the rs2227481 T and homozygous TT genotype may be important in protecting against P. falciparum malaria infection.The IL-22 variant rs2227483 is located within putative binding sites for the aryl-hydrocarbon receptor (AhR-ARNT) complex, and it has been suggested that this complex transcription factor induce IL-22 expression [31]. The AhR-ARNT receptor complex interacts with miscellaneous ligands and is a key in regulating IL-22 production [22]. For the IL-22 rs2227483 polymorphism, the heterozygous AT genotype was significantly associated with protection against P. falciparum infection. Zhang et al. demonstrated that the A and T alleles of IL-22 rs2227483 were significantly elevated in controls compared to tuberculosis (TB) cases and suggested that rs2227483 A and T alleles are associated with increased production of IL-22 decreasing vulnerability to TB infection [32]. Notably, others have found that the rs2227483 genotype TT is statistically associated with early-onset psoriasis through the high production of IL-22 cytokine [31]. Although we did not find any association between the rs2227483 TT genotype and P. falciparum infection, the malaria group possessed a higher TT genotype compared to the controls. Our findings and literature suggest that the variant rs2227483 TT genotype could have a role in the altered IL-22 expression and increased risk of malaria infection.As parasite density is associated with a more severe outcome inP. falciparum malaria [33, 34], we analyzed our data in relation to parasite density. The only variant that had a statistically significant distribution is rs2227481 when cohorts I+II+III were compared to cohort IV. This SNP is located upstream of the IL-22 gene and could influence the expression levels of the protein; however, the conclusion should be substantiated by experimental evidence.TheIL-22 gene polymorphism rs2046068 was not statistically associated with either protection or risk of malaria infection or the level of parasite density. Similarly, Weger et al. did not find any relationship of the rs2046068 genotype and haplotype analysis with chronic plaque psoriasis [35]. In the current study, the rs2046068 AA genotype was higher in the control group. Song et al. also showed an elevated rs2046068 AA genotype in the control group in contrast to a group with autoimmune thyroid disease (AITD), Graves’ disease (GD), and Hashimoto’s thyroiditis (HT). However, the relationship was not statistically significant [36]. We found that the rs2046068 A allele in the IL-22 gene was statistically high under a dominant mode of inheritance in the malaria group within the 1-5 years age group compared to the 6 years and older age group. Conversely, the frequency of the rs2046068 C allele was predominant in the malaria group, 6 years and older, in a dominant inheritance model.The haplotype distribution analysis at theIL-22 gene demonstrated statistically significant frequencies between the control and P. falciparum-infected malaria groups. We detected a high frequency of the rs1179246-rs1182844-rs976748 A-T-T haplotype in the control group compared to the malaria group, suggesting the role of the A-T-T haplotype in protecting against P. falciparum infection. Similarly, an elevated frequency of the rs2046068-rs2227491 A-G haplotype was observed in the control group. Wang et al. did not find any association between the rs2227491 and serum IL-22 levels of the control group in SLE cases in a Chinese population [20]. With the haplotype analysis for the level of parasite density when comparing cohort I+II with III+IV, the results showed a significantly higher frequency of the rs1179246-rs1182844-rs2046068-rs2227491-rs2227481-rs2227478 C-A-C-A-C-C haplotype in the I+II cohort. The contribution of these haplotypes to P. falciparum-associated clinical outcomes and the function of IL-22 need to be experimentally substantiated.The variant rs2227513 is positioned at the first intron of theIL-22 gene and it is also part of the promoter region of the IL-22 gene. Studies suggest that introns are imperative modulators of gene functions such as RNA editing [37, 38]. In the current study, the IL-22 rs2227513 G allele was associated with higher expression levels of the IL-22 cytokine, as evidenced by statistically higher luciferase reporter gene activity. Although this SNP was excluded from the test of association analysis due to the significant deviation from HWE, it is almost a complete LD (r2=0.98) with rs976748, associated with a higher risk of P. falciparum malaria infection.Several studies have shown that variations at the IL-22 gene could contribute to the outcome of different diseases. Mastelic et al. demonstrated a shielding role of IL-22 cytokine againstP. chabaudi-induced liver damage [23]. Also, Hu et al. reported a high possibility of HIV infection with the rs2227513 AG genotype [39]. It was also suggested that there is a positive association between the rs2227513 AG genotype and susceptibility to SLE [20]. The latter study showed that the levels of the IL-22 cytokine were statistically less in the AG genotype in contrast to AA genotype, signifying that the rs2227513 AG genotype increases the risk of SLE by reducing the IL-22 cytokine levels [20]. Our findings indicate a potential pathological role of the rs2227513 G allele in malaria infection, evidenced by the higher promoter activity in the luciferase assay.This study suggests that variants in theIL-22 gene may produce different roles in the vulnerability to infection in populations with diverse ethnic backgrounds. A plausible explanation of this disparity could be environmental or other genetic elements. As we did not investigate all the IL-22 gene variants, future case control studies are necessary to confirm the findings of this study and to explore additional links between IL-22 SNPs and the clinical outcome of P. falciparum-associated malaria. It is essential to reproduce a similar study in other populations with a different genetic background to replicate our findings in a larger sample size. In addition, studies to outline the molecular or cellular mechanisms underlying the role of IL-22 in malaria are recommended.


## 5. Conclusion

Our data shows that the IL-22 rs2227481 TT genotype and T allele and the rs2227483 AT genotype and A allele may be associated with protection againstP. falciparum malaria. The IL-22 promoter polymorphism in rs2227513 G allele appears to be associated with higher expression levels of IL-22, which could play a role in the protection against the disease. These findings will increase the current understanding of the mechanisms involved in the pathogenesis of malaria infection.



---

*Source: 5193723-2020-02-19.xml*